{"title":"Pharmacology Books","description":"","products":[{"product_id":"new-guide-to-medicine-and-drugs-9780241471029","title":"New Guide to Medicine and Drugs","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e","brand":"Dorling Kindersley Ltd","offers":[{"title":"Default Title","offer_id":47832787812695,"sku":"9780241471029","price":18.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780241471029.jpg?v=1719843172"},{"product_id":"concise-guide-to-medicine-drugs-7th-edition-9780241490327","title":"Concise Guide to Medicine  Drugs 7th Edition","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eThe complete home reference to more than 3000 drugs used to treat most major conditions.\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003eFrom how drugs work to practical advice on the uses, side effects, and risks associated with different prescription medicines and over-the-counter drugs, this medicine book explains it all.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eInside the pages of Concise Guide to Medicine \u0026amp; Drugs, you''ll find:\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e- Drugs are organised clearly in an A-Z format, with principal drugs groups arranged by body system or disease group\u003cbr\u003e- Text-only section on how major drug groups work on the body\u003cbr\u003e- Updated Drug Finder index that lists 3,000 generic and brand-name drugs available in the UK\u003cbr\u003e\u003cbr\u003eClear, concise and jargon-free, this book about medicine offers essential guidance for anyone taking medication and is an ideal quick-reference guide for healthcare professionals and carers. It is also great for anyone wanting to know more about the drugs used in common medical practice.\u003cbr\u003e\u003cbr\u003eYou''ll discover what to do if a\u003c\/p\u003e","brand":"Dorling Kindersley Ltd","offers":[{"title":"Default Title","offer_id":47832809439575,"sku":"9780241490327","price":9.49,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780241490327.jpg?v=1710338516"},{"product_id":"say-why-to-drugs-9781473686243","title":"Say Why to Drugs","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003eA definitive and authoritative guide to drugs and why we get high from the creator of the top-rated podcast, Say Why to Drugs.  Drugs. We''ve all done them. Whether it''s a cup of coffee or a glass of wine, a cigarette or a sleeping pill. But how well do we understand the effects of the drugs we take - legal or illegal?  Say Why to Drugs investigates the science behind recreational drugs- debunking common myths and misconceptions, as well as containing the most recent scientific research. Looking at a range of drugs, this book provides a clear understanding of how drugs work and what they''re really doing to your mind and body.  Along the way you will find out why ketamine is on the WHO''s list of essential medicines, why some researchers hope MDMA could treat PTSD, and much more.  Enlightening, entertaining, and thought-provoking, Say Why to Drugs is a compelling read that will surprise and educate proponents on both sides of the drugs debat\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003eSuzi Gage cuts through all the sensationalism and goes straight into an erudite, evidence based breakdown. In an area where factual accuracy is often rejected in favour of moralising or panicking this book is a vitally useful and frequently fascinating. \u003cb\u003e-- Robin Ince\u003c\/b\u003e\u003cbr\u003eAn essential read. Drugs have a huge impact on our society. Whether you're taking them on not, it's good to be informed. \u003cb\u003e-- Tim Lovejoy\u003c\/b\u003e\u003cbr\u003eAn excellently written, ironically clear-headed, and much needed book... that tells you all the important stuff worth knowing about drugs. -- \u003cb\u003eDean Burnett, author of \u003ci\u003eThe Idiot Brain\u003c\/i\u003e and \u003ci\u003eThe Happy Brain \u003c\/i\u003e\u003c\/b\u003e\u003cbr\u003eIt's so refreshing to read a book about drugs which fully acknowledges the complex, nuanced psychological aspects of addiction and that we're all somewhere on that scale. Written without making sweeping moral judgements and faithful to the science, this is a great overview for anyone who wants to educate themselves on a massive (and often emotive) topic. \u003cb\u003e-- Natasha Devon, LBC\u003c\/b\u003e","brand":"Hodder \u0026 Stoughton","offers":[{"title":"Default Title","offer_id":47851811537239,"sku":"9781473686243","price":10.44,"currency_code":"GBP","in_stock":true}]},{"product_id":"drugs-in-palliative-care-9780198746409","title":"Drugs in Palliative Care","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eWhile palliative care has adopted a holistic approach to treatment, medication driven symptom management ostensibly forms the critical aspect of care. Prescribing in palliative care can be extremely complex because the patient may often have comorbidity, or occasionally multimorbidity. The associated polypharmacy further complicates the pharmacological management of symptoms being caused by the palliative condition. This can be daunting for healthcare professionals and can negatively impact upon the effectiveness of care provided.Fully revised and updated, the third edition of Drugs in Palliative Care provides an accessible and succinct overview of the main drugs that are encountered in palliative care clinical practice. The text begins by providing a clinical pharmacology overview and prescribing guidance, then contains over 160 monographs of palliative care drugs, in an easy to access A-Z format.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003eReview from previous edition I like the handy pocket-size and the drug monographs are organised in an easy-to-use A-Z format. This book would be very useful as a quick reference on any palliative care unit. * IAHPC Newsletter *\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eDetailed contents Symbols and abbreviations 1: Clinical pharmacology overview 2: Prescribing guidance 3: Drug Monograph A-Z Index","brand":"Oxford University Press","offers":[{"title":"Default Title","offer_id":48732776071511,"sku":"9780198746409","price":36.09,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780198746409.jpg?v=1719998349"},{"product_id":"drug-design-and-development-9780198749318","title":"Drug Design and Development","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eDrug Design and Development outlines the processes involved in the design and development of new drugs and emphasises the significance of these processes to the practice of pharmacy. The book highlights why it is important that all practicing pharmacists, including those working in hospitals or high street stores, have a solid understanding of the process of the design and development of the drugs they interact with. It adopts an integrated approach, formulated to complement courses which are designed in line with the General Pharmaceutical Council''s new curriculum requirements. Furthermore, this is the only integrated textbook to consider both drug design and development within one volume. Throughout the book, the journey of the drug, from discovery to market, is presented in an integrated fashion, emphasising the interconnection of all the processes involved.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003eWell written text that guides students through the complex elements of the drug development process. It has a chemistry focus and utilises 'key points' to reinforce the important aspects at regular opportunities. * Dr James F. Brown, University of Portsmouth *\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1: Introduction Part 1 Drug targets 2: Receptors and signal transduction 3: Enzymes as drug targets 4: Nucleic acids and protein synthesis as drug targets 5: Other drug targets Part 2 Origins of drug molecules 6: Sources of lead compounds 7: Drug synthesis 8: Optimisation of lead compounds 9: Computer-aided drug design 10: Combinatorial chemistry and high-throughput screening 11: Biotechnology and biopharmaceuticals Part 3 Biological aspects of drug development 12: Drug metabolism 13: Pharmacogenetics and pharmacogenomics 14: Toxicity testing Part 4 Preformulation studies 15: Solubility and drug development 16: Solid state characteristics 17: Drug stability Part 5 Clinical research 18: Clinical research and its regulation 19: Design and management of clinical trials","brand":"Oxford University Press","offers":[{"title":"Default Title","offer_id":48732777054551,"sku":"9780198749318","price":37.99,"currency_code":"GBP","in_stock":true}]},{"product_id":"oxford-handbook-of-practical-drug-therapy-9780199562855","title":"Oxford Handbook of Practical Drug Therapy","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis Handbook mirrors the leading national guides to prescribing. The safe and effective use of medicine requires a sound knowledge of pharmacology. As readers use this practical book, they will increase their knowledge.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003eI would recommend the Oxford Handbook of Practical Drug Therapy for both use on the wards and for revision for medical school exams. . . Its in depth cover of relevant prescribing information will make it a useful resource for junior doctors as well as medical students. * Lucy Faulkner, Northwing Magazine Sheffield University Medical Students Magazine *\u003cbr\u003eThis is a small compact and easy to utilise drug therapy manual. Overall a well set out easy to follow guide that would be useful for health professionals of all levels. * ANTS Bulletin *\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eIntroductory sections ; 1. Gastrointestinal system ; 2. Cardiovascular system ; 3. Respiratory system ; 4. Central nervous system ; 5. Infections ; 6. Endocrine system ; 7. Kidneys and the urinary tract ; 8. Malignant disease and immunosuppression ; 9. Nutrition and blood ; 10. Musculoskeletal and joints ; 11. Eye ; 12. Skin ; 13. Poisoning ; 14. Immunological products and vaccines ; 15. Relief of pain and anaesthetic drugs","brand":"Oxford University Press","offers":[{"title":"Default Title","offer_id":48732865364311,"sku":"9780199562855","price":32.29,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780199562855.jpg?v=1719998727"},{"product_id":"cannabinoids-and-the-brain-the-mit-press-9780262536608","title":"Cannabinoids and the Brain The MIT Press","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eA review of the scientific evidence on the effects of cannabinoids on brain and behavioral functioning, with an emphasis on potential therapeutic use.\u003cbr\u003e\u003c\/b\u003e\u003cbr\u003eThe cannabis plant has been used for recreational and medicinal purposes for more than 4,000 years, but the scientific investigation into its effects has only recently yielded useful results. In this book, Linda Parker offers a review of the scientific evidence on the effects of cannabinoids on brain and behavioral functioning, with an emphasis on potential therapeutic uses.\u003cbr\u003e\u003cbr\u003eParker describes the discovery of tetrahydocannbinol (THC), the main psychoactive component of cannabis, and the further discovery of cannabinoid receptors in the brain. She explains that the brain produces chemicals similar to THC, which act on the same receptors as THC, and shows that the endocannabinoid system is involved in all aspects of brain functioning. Parker reports that cannabis contains not only the psychoactive compound THC, but also","brand":"MIT Press Ltd","offers":[{"title":"Default Title","offer_id":48733468164439,"sku":"9780262536608","price":22.2,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780262536608.jpg?v=1720000189"},{"product_id":"brodys-human-pharmacology-9780323476522","title":"Brodys Human Pharmacology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eSection 1 Mechanisms of Drug Action and Therapeutic Principles   1. Introduction, Terminology   2. Pharmacodynamics: Drug Targets (Receptors, Enzymes, DNA, etc)   3. Pharmacokinetics   4. Pharmacogenomics   5. Drug Discovery, Development, and Regulation   Section 2 Chemical Mediators and Drugs Affecting Autonomic and Neuromuscular Synapses   6. Introduction to the Peripheral Nervous Systems and Drugs for Peripheral Disorders   Cholinergic Drugs   7. Muscarinic Agonists and Their Clinical Uses   8. Muscarinic Antagonists and Their Clinical Uses   9. Nicotinic Agonists and Their Clinical Uses   10. Nicotinic Antagonists and Neuromuscular Blocking Drugs   Adrenergic Drugs   11. Adrenergic Agonists and Their Clinical Uses   12. Adrenergic Antagonists and Their Clinical Uses   Section 3 Drug Treatment for Disorders Affecting the Central Nervous System   13. Introduction to the CNS and Drugs Affecting the Brain   Neurodegenerative Disorders   14. Drug Therapy for Alzheimer's Disease and Other Cognitive Disorders\/Dementias   15. Pharmacotherapy of Basal Ganglia Disorders: Parkinson's Disease and Huntington's Disease   16. Drug Therapy for Psychoses and Bipolar Disorder   17. Drug Therapy for Depression and Anxiety   18. Drug Therapy for the Management of Attention Deficit Hyperactivity Disorder   19. Drug Therapy for Insomnia and the Hypersomnias   20. Drug Therapy for Managing Obesity and Eating Disorders   21. Treatment of Seizure Disorders   22. Drug Therapy to Control Spasticity Disorders   23. Ethanol, Other Alcohols, and Drugs for Alcohol Use Disorder   24. Illicit Psychoactive Compounds and Substance Use Disorder   Section 4 Drug Therapy for Pain Management   25. Introduction   26. General Anesthetics   27. Local Anesthetics   28. Opioid Analgesics   29. Nonsteroidal Anti-inflammatory Agents and Acetaminophen   30. Cannabinoids   Section 5 Treatment of Inflammatory, Allergic and Immunologic Disorders   31. Drug Therapy for Migraine Headache    32. Drug Therapy for Gout and Hyperuricemia   33. Drug Treatment for Allergic Reactions   34. Immunosuppressants for Autoimmune Disorders and Organ Transplantation   35. Drug Therapy for Rheumatoid Arthritis   Section 6 Drug Treatment for Cardiovascular Diseases   36. Introduction to The Cardiovascular System and the Regulation of Blood Pressure and Heart Rate   37. Overview of Hypertension Management and Drugs that Decrease Sympathetic Tone   38. Diuretics and Drugs that Affect Volume and Electrolyte Content   39. Drugs Affecting the Renin-Angiotensin-Aldosterone System   40. Calcium Channel Blockers   41. Vasodilators   42. Drug Therapy for Hyperlipidemias and Atherosclerotic Cardiovascular Disease   43. Drug Therapy for Myocardial Ischemia and Angina Pectoris   44. Treatment of Heart Failure: Cardiac Glycosides, Phosphodiesterase Inhibitors and Other Agents   45. Antiarrhythmic Drugs   46. Anticoagulant, Antiplatelet and Thrombolytic Agents   47. Drug Therapy for Hemophilia and the Anemias   Section 7 Treatment of Endocrine Disorders   48. Introduction to Endocrine Pharmacology   49. Treatment of Hypothalamic and Pituitary Disorders   50. Treatment of Adrenalcorticosteroid Disorders   51. Female Hormone Regulation   52. Androgens, antiandrogens and their clinical uses   53. Drug Therapy for the Management of Diabetes   54. Drug Therapy for the Management of Thyroid Disorders   55. Calcium Regulating Hormones and Agents Affecting Bone   Section 8 Chemotherapy   Infectious Diseases   56. Principles of Antimicrobial Use   57. Bacterial Cell Wall Synthesis Inhibitors   58. Inhibitors of Protein Synthesis   59. Drugs that Target DNA   60. Antimycobacterial Drugs and the Treatment of Tuberculosis and Leprosy   61. Drug Therapy for Resistant Organisms   Parasitic Diseases   62. Antifungal Agents   63. Antimalarial and Other Antiprotozoal Agents   64. Antihelmintics   Viruses   65. Drug Therapy for non-HIV Viral Infections   66. Drugs for HIV and Related Opportunistic Infections   Cancer   67. Introduction and Therapeutic Principles   68. Cytotoxic Agents   69. Targeted Agents   Section 9 Special Considerations   70. Therapeutic Use of Hematopoietic Growth Factors, Vitamins and Minerals   71. Gastrointestinal Disorders and Their Treatment   72. Pharmacological Treatment of Asthma and COPD    73. The Role of Neutraceuticals and Natural Products   74. Essentials of Toxicology   75. Therapeutic Considerations for Pregnant, Pediatric, Geriatric and Obese Individuals","brand":"Elsevier - Health Sciences Division","offers":[{"title":"Default Title","offer_id":48733599596887,"sku":"9780323476522","price":56.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780323476522.jpg?v=1720000785"},{"product_id":"raus-respiratory-care-pharmacology-9780323553643","title":"Raus Respiratory Care Pharmacology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eUnit I: Basic Concepts and Principles in Pharmacology  1. Introduction to Respiratory Care Pharmacology 2. Principles of Drug Action 3. Administration of Aerosolized Agents 4. Calculating Drug Doses 5. The Central and Peripheral Nervous Systems   Unit II: Drugs Used to Treat the Respiratory System 6. Adrenergic (Sympathomimetic) Bronchodilators 7. Anticholinergic (Parasympatholytic) Bronchodilators 8. Xanthines 9. Mucus-Controlling Drug Therapy 10. Surfactant Agents 11. Corticosteriods in Respiratory Care 12. Nonsteroidal Antiasthma Agents 13. Aerosolized Antiinfective Agents 14. Antimicrobial Agents 15. Cold and Cough Agents 16. Selected Agents of Pulmonary Value 17. Neonatal and Pediatric Aerosolized Drug Therapy   Unit III: Critical Care, Cardiovascular, and Polysomnography Agents 18. Skeletal Muscle Relaxants (Neuromuscular Blocking Agents) 19. Diuretic Agents 20. Drugs Affecting the Central Nervous System  21. Vasopressors, Inotropes, and Antiarrythmic Agents  22. Drugs Affecting Circulation: Antihypertensives, Antianginals, Antithrombotics 23. Sleep and Sleep Pharmacology   Appendix A: Answers to Self-Assessment Questions and Clinical Scenarios Appendix B: Units and Systems of Measurement Appendix C: Acceptable Mixtures of Most Commonly Prescribed Respiratory Care Drugs Glossary of Selected Terms Drug Index Abbreviations","brand":"Elsevier - Health Sciences Division","offers":[{"title":"Default Title","offer_id":48733600055639,"sku":"9780323553643","price":77.34,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780323553643.jpg?v=1720000787"},{"product_id":"pharmacology-essentials-for-allied-health-text-with-student-cd-text-with-course-navigator-9780763858629","title":"Pharmacology Essentials for Allied Health Text","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eCovers the full range of pharmacology concepts at the need-to-know level. Content is organized by major body system to help students understand the connections between particular body systems and drug therapy. The text teaches students about the major diseases and illnesses that originate in or affect body systems, along with the specific drug therapies used in their treatments.","brand":"EMC Paradigm,US","offers":[{"title":"Default Title","offer_id":48737189200215,"sku":"9780763858629","price":999.99,"currency_code":"GBP","in_stock":false}]},{"product_id":"a-handbook-of-native-american-herbs-healing-arts-the-pocket-guide-to-125-medicinal-plants-and-their-uses-9780877736998","title":"A Handbook of Native American Herbs Healing Arts","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eThe author of ‘the bible on herbalism’ returns with a portable guide on North American medicinal herbs—for the professional and amateur herbalist alike\u003cbr\u003e \u003c\/b\u003e\u003cbr\u003e Based on the now-classic reference text \u003ci\u003eIndian Herbalogy of North America\u003c\/i\u003e, this illustrated pocket guide is the perfect companion for those eager to expand their knowledge of herbal healing. Through detailed descriptions and illustrations, Alma R. Hutchens walks readers through:\u003cbr\u003e\u003cbr\u003e• 125 of the most useful medicinal herbs found in North America, and their uses\u003cbr\u003e• How to create herbal remedies for common ailments\u003cbr\u003e• The herbal traditions of North America and other lands\u003cbr\u003e\u003cbr\u003e Entries include staples of folk medicine such as echinacea and slippery elm as well as common kitchen herbs—from parsley to thyme to pepper—whose tonic and healing properties are less widely known.","brand":"Shambhala Publications Inc","offers":[{"title":"Default Title","offer_id":48737793769815,"sku":"9780877736998","price":15.29,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780877736998.jpg?v=1723811468"},{"product_id":"case-studies-stahls-essential-psychopharmacology-volume-3-9781009012898","title":"Case Studies Stahls Essential Psychopharmacology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eFollowing the success of the first two volumes in Stahl''s Case Studies series, a brand new collection of clinical stories have been collated in Volume 3, derived from cases seen by medical students, residents and faculty from the University of California at Riverside (UCR) Department of Psychiatry and Neuroscience. The highly popular and unique user-friendly presentation of previous volumes has been maintained, with extensive use of icons, questions\/answers, and tips. The cases address multifaceted issues in an understandable way and with direct relevance to the everyday experience of clinicians. Covering a wide-ranging and representative selection of clinical scenarios, each case is followed through the complete clinical encounter, from start to resolution, acknowledging all the complications, issues, decisions, twists and turns along the way. The book is about living through the treatments that work, the treatments that fail, and the mistakes made along the journey. This is psychiat\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e'I am delighted to see the new volume. It is a very welcome, important complement to Stahl's Essential Psychopharmacology. While presenting several interesting and timely cases that will allow practitioners in mental health to hone their skills and update their psychopharmacology knowledge, it is also a delightful read. Well done!' Jair C. Soares, Professor and Chairman, Pat Rutherford Chair in Psychiatry, Director, UT Center of Excellence on Mood Disorders, Louis Faillace, M.D Department of Psychiatry and Behavioral Sciences, UT Houston Medical School, Houston, USA\u003cbr\u003e'This book offers readers a comprehensive approach to complex, real world psychopharmacological dilemmas based on actual clinical cases that are followed over time. Each case identifies critical questions at important junctures of treatment and expertly breaks down the thought processes involved in decision making of challenging yet common and recognizable clinical scenarios. The authors demonstrate how to apply the art and science of psychopharmacology with careful in-depth dissections of each case, outside of the box thinking and a large dose of humility. Readers will appreciate the case discussions where authors share their confessions as psychopharmacologists and retrospective self-assessments of what they could have done better. Case Studies: Stahl's Essential Psychopharmacology distils years of clinical experience with up-to-date clinical psychopharmacology into a practical text for all psychiatric practitioners.' Poh Choo How, MD, PhD, Assistant Professor, Department of Psychiatry and Behavioral Sciences, University of California, Davis, Sacramento\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1. The case: Wearing down a diagnosis Karen Clarey, Stephanie Wong and Takesha Cooper; 2. The case: The woman who couldn't handle her lips smacking any longer Douglas Grover and Christopher G. Fichtner; 3. The case: The depressed bipolar patient on multiple medications Dale Hoang, Catherin Ha and Peter Hauser; 4. The case: The agitated patient who finally wasn't Alexander J Mageno, Nekisa Haghighat, Arthur Leitzke; 5. The case: The George that was not psychotic but anxious and distracted Edgar Ortega, Michael Seigler and Takesha Cooper; 6. The case: The man who saw enemies everywhere Joshua Poole and Stephen Maurer; 7. The case: The young woman with psychosis complicated by substance use and history of TBI Harika Reddy, Austin Nguy and Sana Johnson-Quijada; 8. The case: The woman with worsening psychosis and a mysterious rash Sireena Sy, Yatna Patel and Alexander Thanh Nguyen; 9. The case: The man without a plan Alfonso Vera and Gerald Maguire; 10. The case: The anxious depressed woman who couldn't sit still Nekisa Haghighat, Charity Hall, Dennis Alters and Gerald Maguire; 11. The case: The man who thinks it's the end of the world Erin Fletcher, Evagelos Coskinas and Phuong Vo; 12. The case: Sunny with a chance of depression Madeline Saavedra, Bo Ram Yoo, Douglas Grover and Christopher G. Fichtner; 13. The case: A not-so-simple case of anxiety Karla P. Furlong, Roberto Castaños and Bo Ram Yoo; 14. The case: I'm a woman in a man's body Sarah Grace, Matt Jason V. Llamas and Jami Woods; 15. The case: The spacey, fidgety son with overwhelming sadness Niya Larios, Casey Lester and Carl Feinstein; 16. The case: The man who spent thousands online Saloni Singh; 17. The case: The traumatized mother who can't stop bingeing Kevin Simonson and Bo Ram Yoo; 18. The case: The man who could not stop hitting people Angharad Ames and Lawrence Faziola; 19. The case: Brexpiprazole: 'An awakening' Troy Kurz, Lauren Kurz and ***Kamal; 20. The case: Treatment resistant depression and opioid dependence Kevin Simonson and Alexander H. Truong; 21. The case: Stiff patient Angharad Ames, Joshua Valverde and Gerald Maguire; 22. The case: An adolescent awakening Monish Parmar and Richard J. Lee; 23. The case: The peace keeper with a left breast mass Diem Nguyen and Brenda Jensen; 24. The case: The girl who slept with problems Joseph Yasmeh and Ijeoma Ijeaku; 25. The case: Not all child's play: a path to pediatric stability Joseph Wong, Justine Ku and Takesha Cooper; 26. The case: The young woman who was 'nothing but skin and bones. Kayla L. Fisher and Michelle Tom; 27. The case: Could it be both? Comorbid psychiatric diagnoses Ruqayyah Malik, Margaret Yau and Dennis Alters; 28. The case: Treatment-emergent mania\/hypomania in a depressed patient Kevin Truong and Lawrence Yu; 29. The case: The border between mood and personality Phuong Vo and Ijeoma Ijeaku; 30. The case: The student that wanted to go to rehab Eduardo Javier, Louis May and Martin Sahakyan; 31. The case: The boy who wouldn't (couldn't) listen Alexander J Mageno, Bo Ram Yoo and Richard J. Lee; 32. The case: The patient that went streaking Louis May, Martin Sahakyan and Eduardo Javier; 33. The case: 'Perseverance' Kathleen Lopez, Courtney DiNicola and Niraj Gupta; 34. The case: Clozapine candidate discombobulates compassionate clinicians Darian Vernon, Nishant Prakash and Niraj Gupta.","brand":"Cambridge University Press","offers":[{"title":"Default Title","offer_id":48738000208215,"sku":"9781009012898","price":999.99,"currency_code":"GBP","in_stock":false}]},{"product_id":"practical-psychopharmacology-9781108450744","title":"Practical Psychopharmacology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eAn accessible book for clinicians at all levels of training and experience who prescribe psychiatric medications and wish to better understand the rationale and empirical evidence base behind choosing treatments optimally tailored to the needs of individual patients.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e'Psychopharmacology textbooks are typically either scholarly, endlessly long and inaccessible to clinicians, or clinician-friendly but with inadequate documentation for readers who want more detailed information. Somehow, Goldberg and Stahl's Practical Psychopharmacology combines the best of these two styles. It is astonishingly comprehensive with many Tables citing every relevant study while simultaneously providing the deep practical wisdom and experience of the two authors, both of whom are world class clinician-scholars. Practical Psychopharmacology also provides a sophisticated yet accessible review of the biological underpinnings of both psychopathology and medication effects. It does not just inform; it teaches the reader how to think about medications. This book will set the standard in our field for the foreseeable future.' Michael Gitlin, Distinguished Professor of Clinical Psychiatry, Director, Adult Division of Psychiatry, Director, Mood Disorders Clinic, Geffen School of Medicine at UCLA\u003cbr\u003e'The translation of clinical research findings into practice is fraught. The methodology of many trials is imperfect, complex, and opaque and hard to generalise to real world patients. Many critical questions are poorly answered by the extant evidence. The basic neuroscience is extraordinarily complex. This book is a Rosetta stone for translating this evidence into practice in providing a critical bridge for practising clinicians in distilling and interpreting the evidence into clear and coherent pragmatic management and prescribing recommendations. Written by two of the world's premier authorities, it is infused with a rare synergy of clinical wisdom and neuroscience expertise and is an essential resource for any practising prescriber of psychotropic agents.' Michael  Berk, NHMRC Senior Principal Research Fellow; Alfred Deakin Professor of Psychiatry, School of Medicine, Deakin University and Barwon Health; Director, IMPACT, the Institute for Mental and Physical Health and Clinical Translation\u003cbr\u003e'Drs. Goldberg and Stahl have reminded us that they are scientific artisans by creating a pragmatic, patient-centered set of guiding principles in clinical psychopharmacology. The emergence of newer psychopharmacologic treatments and expansion of indications for previously available agents has provided hope for identifying therapeutic avenues for patients to improve their general wellbeing, but also can feel daunting, overwhelming, and a source of entropy. Consequently, it is not uncommon for clinicians at point of care to be genuinely perplexed as to which treatments and capabilities are 'promising rather than prime-time'. The authors have deftly synthesized the scientific literature and have produced a book that is comprehensive, concise, and an invaluable source of decision support at the point of care for multidisciplinary practitioners who provide care to persons with mental disorders.' Roger S. McIntyre, Professor of Psychiatry and Pharmacology and Head, Mood Disorders Psychopharmacology Unit, University of Toronto, Canada\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePart I. General Principles: 1. Core concepts of good psychopharmacology; 2. Targets of treatment: categories versus dimensions of psychopathology; 3. Interpreting and using the literature: integrating evidence-based trials with real-world practice; 4. Placebo and nocebo effects; 5. Tailoring the fit: moderators and mediators of treatment outcome; 6. Complex regimens and rationale-based combination drug therapies; 7. Laboratory values and psychiatric symptoms: what to measure, what not to measure, and what to do with the results; 8. Pharmacogenetics: when relevant, when not; 9. Cross-tapering and the logistics of drug discontinuation; 10. Managing major adverse drug effects: when to avoid, switch, or treat through; 11. Novel drug therapeutics: nutraceuticals, steroids, probiotics, and other dietary supplements; 12. Human diversity and considerations in special populations; Part II. Targets of Pharmacotherapy: 13. Disordered mood and affect; 14. Disorders of impulsivity, compulsivity, and aggression; 15. Psychosis; 16. Deficit states and negative symptoms; 17. Anxiety; 18. Addiction and the reward pathway; 19. Trauma and posttraumatic stress disorder; 20. Personality disorders; 21. Cognition; 22. Putting it all together; References; Index.","brand":"Cambridge University Press","offers":[{"title":"Default Title","offer_id":48738295218519,"sku":"9781108450744","price":55.09,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781108450744.jpg?v=1723811898"},{"product_id":"cellular-signal-transduction-in-toxicology-and-pharmacology-9781119060260","title":"Cellular Signal Transduction in Toxicology and","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eCovering a key topic due to growing research into the role of signaling mechanisms in toxicology, this book focuses on practical approaches for informatics, big data, and complex data sets.\u003cbr\u003e\u003cbr\u003e \u003cul\u003e \u003cli\u003eCombines fundamentals \/ basics with experimental applications that can help those involved in preclinical drug studies and translational research\u003c\/li\u003e \u003cli\u003eIncludes detailed presentations of study methodology and data collection, analysis, and interpretation\u003c\/li\u003e \u003cli\u003eDiscusses tools like experimental design, sample handling, analytical measurement techniques\u003c\/li\u003e \u003c\/ul\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eList of Contributors xv\u003c\/p\u003e \u003cp\u003eAbout the Editors xvii\u003c\/p\u003e \u003cp\u003ePreface xix\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Introduction to Cellular Signal Transduction: The Connection Between a Biological System and Its Surroundings 1\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJonathan W. Boyd, Richard R. Neubig, Alice Han, \u003c\/i\u003eand\u003ci\u003e Maren Prediger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Starting Big, but Ending Small 3\u003c\/p\u003e \u003cp\u003e1.1.1 Key Features of Signal Transduction 3\u003c\/p\u003e \u003cp\u003e1.2 Responding to Our Environment: Sensory Perception Begins and Ends with Signal Transduction 4\u003c\/p\u003e \u003cp\u003e1.2.1 Taste (Gustation) 4\u003c\/p\u003e \u003cp\u003e1.2.2 Smell (Olfaction) 5\u003c\/p\u003e \u003cp\u003e1.2.3 Sight (Vision) 6\u003c\/p\u003e \u003cp\u003e1.2.4 Sound (Audition) 6\u003c\/p\u003e \u003cp\u003e1.2.5 Touch (Somatosensation) 8\u003c\/p\u003e \u003cp\u003e1.3 Primary Transport Systems Involved in Signal Transduction 8\u003c\/p\u003e \u003cp\u003e1.3.1 Ion Channels, Transporters, and Ion Pumps 9\u003c\/p\u003e \u003cp\u003e1.3.2 Receptors 10\u003c\/p\u003e \u003cp\u003e1.3.3 Endocytosis 10\u003c\/p\u003e \u003cp\u003e1.3.4 Exosomes 11\u003c\/p\u003e \u003cp\u003e1.4 Key Organelles Involved in Signal Transduction 12\u003c\/p\u003e \u003cp\u003e1.4.1 Mitochondria 12\u003c\/p\u003e \u003cp\u003e1.4.2 Endoplasmic Reticulum 14\u003c\/p\u003e \u003cp\u003e1.4.3 Nucleus 15\u003c\/p\u003e \u003cp\u003eReferences 16\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Mechanisms of Cellular Signal Transduction 21\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRichard R. Neubig, Jonathan W. Boyd, Julia A. Mouch, \u003c\/i\u003eand\u003ci\u003e Nicole Prince\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Posttranslational Modifications and Their Roles in Signal Transduction 22\u003c\/p\u003e \u003cp\u003e2.1.1 Phosphorylation 22\u003c\/p\u003e \u003cp\u003e2.1.2 Acylation 24\u003c\/p\u003e \u003cp\u003e2.1.3 Alkylation 25\u003c\/p\u003e \u003cp\u003e2.1.4 Glycosylation 26\u003c\/p\u003e \u003cp\u003e2.1.5 Other PTMs 27\u003c\/p\u003e \u003cp\u003e2.2 Receptors 27\u003c\/p\u003e \u003cp\u003e2.3 Receptor Signaling Mechanisms 29\u003c\/p\u003e \u003cp\u003e2.3.1 Basic Principles of Signal Transduction Mechanisms 29\u003c\/p\u003e \u003cp\u003e2.3.1.1 Selectivity and Recognition 31\u003c\/p\u003e \u003cp\u003e2.3.1.2 Flexible Modularity 31\u003c\/p\u003e \u003cp\u003e2.3.1.3 Molecular Switches 34\u003c\/p\u003e \u003cp\u003e2.3.1.4 GPCRs and Second Messengers 36\u003c\/p\u003e \u003cp\u003e2.3.1.5 Amplification 39\u003c\/p\u003e \u003cp\u003e2.3.1.6 Turn‐Off Mechanisms 40\u003c\/p\u003e \u003cp\u003e2.3.1.7 Localization 40\u003c\/p\u003e \u003cp\u003e2.3.1.8 Biased Signaling\/Functional Selectivity 41\u003c\/p\u003e \u003cp\u003e2.4 Receptor Tyrosine Kinases 42\u003c\/p\u003e \u003cp\u003e2.5 Steroid Receptors 43\u003c\/p\u003e \u003cp\u003e2.6 Reactive Oxygen Species (ROS) 43\u003c\/p\u003e \u003cp\u003e2.7 Summary 44\u003c\/p\u003e \u003cp\u003eReferences 44\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 From Cellular Mechanisms to Physiological Responses: Functional Signal Integration Across Multiple Biological Levels 49\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eRobert H. Newman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 49\u003c\/p\u003e \u003cp\u003e3.2 Cellular Information Flow: Mechanisms of Cellular Signal Integration and Regulation 50\u003c\/p\u003e \u003cp\u003e3.2.1 The InsR‐aPKC‐NF‐κB Signaling Axis 51\u003c\/p\u003e \u003cp\u003e3.2.2 Modes of Regulation in InsR‐PKC‐NF‐κB Signaling Axis 54\u003c\/p\u003e \u003cp\u003e3.2.3 Transcriptional Regulation 54\u003c\/p\u003e \u003cp\u003e3.2.4 Regulating the Regulators: Phosphatase‐Mediated Regulation of Signaling Molecules 59\u003c\/p\u003e \u003cp\u003e3.3 Crosstalk and Functional Signal Integration in Response to Insulin in Hepatocytes 60\u003c\/p\u003e \u003cp\u003e3.4 Systemic Signal Integration 65\u003c\/p\u003e \u003cp\u003e3.4.1 Pancreatic β‐Cells 65\u003c\/p\u003e \u003cp\u003e3.4.2 Skeletal Muscles 66\u003c\/p\u003e \u003cp\u003e3.4.3 Adipose Tissue 67\u003c\/p\u003e \u003cp\u003e3.5 Dysregulation of Insulin Signaling in the Etiology of Type 2\u003c\/p\u003e \u003cp\u003eDiabetes 67\u003c\/p\u003e \u003cp\u003eReferences 69\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Signal Transduction in Disease: Relating Cell Signaling to Morbidity and Mortality 73\u003cbr\u003e\u003c\/b\u003e\u003ci\u003ePatricia E. Ganey and Sean A. Misek\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 73\u003c\/p\u003e \u003cp\u003e4.2 Fibrosis as an Example of Complex Signaling 75\u003c\/p\u003e \u003cp\u003e4.2.1 Development of Liver Fibrosis 75\u003c\/p\u003e \u003cp\u003e4.2.2 Animal Models of Hepatic Fibrosis 76\u003c\/p\u003e \u003cp\u003e4.2.3 Activation of Hepatic Stellate Cells 77\u003c\/p\u003e \u003cp\u003e4.2.4 Epithelial‐to‐Mesenchymal Transition (EMT) 78\u003c\/p\u003e \u003cp\u003e4.2.5 Other Cellular Interactions in Fibrosis 78\u003c\/p\u003e \u003cp\u003e4.2.6 Intracellular Signaling Pathways Critical to Liver Fibrosis 80\u003c\/p\u003e \u003cp\u003e4.2.6.1 TGF‐β1 80\u003c\/p\u003e \u003cp\u003e4.2.6.2 Kinase Pathways Involved in Fibrotic Responses 82\u003c\/p\u003e \u003cp\u003e4.2.6.3 HIF‐1α 83\u003c\/p\u003e \u003cp\u003e4.2.6.4 miRNA 84\u003c\/p\u003e \u003cp\u003e4.2.6.5 Toll‐Like Receptors (TLRs) 84\u003c\/p\u003e \u003cp\u003e4.3 Cancer Drug Resistance: Complex Cellular and Population Changes 85\u003c\/p\u003e \u003cp\u003e4.3.1 Genomic Resistance Mechanisms 85\u003c\/p\u003e \u003cp\u003e4.3.2 Non‐genomic Mechanisms 88\u003c\/p\u003e \u003cp\u003e4.3.3 Non‐cancer Drug Resistance Paradigms 88\u003c\/p\u003e \u003cp\u003e4.3.4 Tumor Heterogeneity as a Driver of Drug Resistance 89\u003c\/p\u003e \u003cp\u003e4.3.5 Mutational Drivers of Drug Resistance 90\u003c\/p\u003e \u003cp\u003e4.3.6 Drug‐Induced Rewiring of Signaling Networks as a Mechanism of Drug Resistance 91\u003c\/p\u003e \u003cp\u003e4.3.7 Parallel Pathways and Combination Treatments 93\u003c\/p\u003e \u003cp\u003e4.3.8 Epigenetic Mechanisms of Drug Resistance 95\u003c\/p\u003e \u003cp\u003e4.3.9 Summary of Cancer Drug Resistance 97\u003c\/p\u003e \u003cp\u003e4.4 Summary 98\u003c\/p\u003e \u003cp\u003eReferences 98\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Experimental Design in Signal Transduction 113\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eWeimin Gao, Meghan Cromie, Qian Wang, Zhongwei Liu, Song Tang, \u003c\/i\u003eand\u003ci\u003e Julie Vrana Miller\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Overview of Basic Experimental Design 113\u003c\/p\u003e \u003cp\u003e5.1.1 Independent Sample \u003ci\u003et\u003c\/i\u003e Test 114\u003c\/p\u003e \u003cp\u003e5.1.2 Completely Randomized Analysis of Variance (ANOVA) 114\u003c\/p\u003e \u003cp\u003e5.1.3 \u003ci\u003et\u003c\/i\u003e Test for Dependent Sample Design 115\u003c\/p\u003e \u003cp\u003e5.1.4 Randomized Block Design 115\u003c\/p\u003e \u003cp\u003e5.1.5 Completely Randomized Factorial Design 116\u003c\/p\u003e \u003cp\u003e5.1.6 Summary 116\u003c\/p\u003e \u003cp\u003e5.2 Aseptic Technique 116\u003c\/p\u003e \u003cp\u003e5.2.1 Sterile Work Environment and Laminar‐Flow Hood 117\u003c\/p\u003e \u003cp\u003e5.2.2 Good Personal Hygiene Practices 117\u003c\/p\u003e \u003cp\u003e5.2.3 Sterile Reagents and Materials 118\u003c\/p\u003e \u003cp\u003e5.2.4 Sterile Handling 118\u003c\/p\u003e \u003cp\u003e5.3 Biological Sample Collection, Processing, and Pretreatment Technology 119\u003c\/p\u003e \u003cp\u003e5.3.1 Sample Collection 119\u003c\/p\u003e \u003cp\u003e5.3.1.1 Sample Collection \u003ci\u003eIn Vivo\u003c\/i\u003e 119\u003c\/p\u003e \u003cp\u003e5.3.1.2 Cell Culture \u003ci\u003eIn Vitro\u003c\/i\u003e 120\u003c\/p\u003e \u003cp\u003e5.3.2 Sample Processing 121\u003c\/p\u003e \u003cp\u003e5.3.2.1 DNA Isolation 121\u003c\/p\u003e \u003cp\u003e5.3.2.2 RNA Extraction 121\u003c\/p\u003e \u003cp\u003e5.3.2.3 Protein Extraction 122\u003c\/p\u003e \u003cp\u003e5.4 Sample Storage 122\u003c\/p\u003e \u003cp\u003e5.5 Common \u003ci\u003eIn Vitro\u003c\/i\u003e Studies in Toxicology\/Pharmacology 123\u003c\/p\u003e \u003cp\u003e5.5.1 Cytotoxicity Studies 123\u003c\/p\u003e \u003cp\u003e5.5.2 Viability Assays 123\u003c\/p\u003e \u003cp\u003e5.5.2.1 Trypan Blue 123\u003c\/p\u003e \u003cp\u003e5.5.2.2 Erythrosin 124\u003c\/p\u003e \u003cp\u003e5.5.2.3 Crystal Violet Staining 124\u003c\/p\u003e \u003cp\u003e5.5.2.4 Neutral Red Staining 125\u003c\/p\u003e \u003cp\u003e5.5.3 Survival Assays 125\u003c\/p\u003e \u003cp\u003e5.5.3.1 Clonogenic or Colony Formation Assay 125\u003c\/p\u003e \u003cp\u003e5.5.3.2 Cell Cycle Analysis: Flow Cytometry 126\u003c\/p\u003e \u003cp\u003e5.5.4 DNA Damage Assays 126\u003c\/p\u003e \u003cp\u003e5.5.4.1 Comet Assay 127\u003c\/p\u003e \u003cp\u003e5.5.4.2 Sister Chromatid Exchange Assay 127\u003c\/p\u003e \u003cp\u003e5.5.5 Southern Blot and DNA Sequencing 127\u003c\/p\u003e \u003cp\u003e5.5.5.1 Southern Blot 127\u003c\/p\u003e \u003cp\u003e5.5.5.2 DNA Sequencing 128\u003c\/p\u003e \u003cp\u003e5.5.5.3 Transfection and Gene Silencing 128\u003c\/p\u003e \u003cp\u003e5.5.6 RNA Quantification and Identification 128\u003c\/p\u003e \u003cp\u003e5.5.6.1 Northern Blot 128\u003c\/p\u003e \u003cp\u003e5.5.6.2 Promoter Deletion Analysis 129\u003c\/p\u003e \u003cp\u003e5.5.6.3 RNase Protection Assay 129\u003c\/p\u003e \u003cp\u003e5.5.7 Gene Expression 129\u003c\/p\u003e \u003cp\u003e5.5.7.1 Quantitative Real‐Time Polymerase Chain Reaction (qRT‐PCR) 130\u003c\/p\u003e \u003cp\u003e5.5.7.2 Microarray 130\u003c\/p\u003e \u003cp\u003e5.5.8 Protein‐Related Assays 131\u003c\/p\u003e \u003cp\u003e5.5.8.1 Bradford Assay 131\u003c\/p\u003e \u003cp\u003e5.5.8.2 Enzyme-Linked Immunosorbent Assay (ELISA) 131\u003c\/p\u003e \u003cp\u003e5.5.8.3 Western Blot and 2D Gel Electrophoresis 131\u003c\/p\u003e \u003cp\u003e5.5.8.4 Immunolocalization 132\u003c\/p\u003e \u003cp\u003e5.5.8.5 Immunoprecipitation Assays 132\u003c\/p\u003e \u003cp\u003e5.5.8.6 Chromatin Immunoprecipitation (ChIP) 132\u003c\/p\u003e \u003cp\u003e5.5.9 Epigenetics 133\u003c\/p\u003e \u003cp\u003e5.5.9.1 Bisulfite Pyrosequencing 133\u003c\/p\u003e \u003cp\u003e5.5.9.2 ChIP‐on‐Chip 133\u003c\/p\u003e \u003cp\u003e5.5.9.3 Multiplex miRNA Profiling 134\u003c\/p\u003e \u003cp\u003e5.6 Common \u003ci\u003eIn Vivo\u003c\/i\u003e Studies in Toxicology 134\u003c\/p\u003e \u003cp\u003e5.6.1 Toxicological Endpoints 134\u003c\/p\u003e \u003cp\u003e5.6.1.1 Maximum Tolerated Dose (MTD) 134\u003c\/p\u003e \u003cp\u003e5.6.1.2 Acute, Subchronic, and Chronic Toxicity 135\u003c\/p\u003e \u003cp\u003e5.6.1.3 Reproductive and Developmental Toxicity 135\u003c\/p\u003e \u003cp\u003e5.6.1.4 Genotoxicity and Carcinogenicity Studies 136\u003c\/p\u003e \u003cp\u003e5.6.2 Routes of Exposure 136\u003c\/p\u003e \u003cp\u003e5.6.2.1 Oral, Dermal, and Inhalation 136\u003c\/p\u003e \u003cp\u003e5.6.2.2 Exposure via Injection 137\u003c\/p\u003e \u003cp\u003e5.6.3 Animal Models 137\u003c\/p\u003e \u003cp\u003e5.6.3.1 Rodent Studies 137\u003c\/p\u003e \u003cp\u003e5.6.3.2 Other Studies 138\u003c\/p\u003e \u003cp\u003e5.7 Basic Advantages and Disadvantages Associated with Sample Types 138\u003c\/p\u003e \u003cp\u003e5.8 Human Epidemiology Studies 138\u003c\/p\u003e \u003cp\u003e5.8.1 Nonexperimental Studies 139\u003c\/p\u003e \u003cp\u003e5.8.2 Experimental Studies 139\u003c\/p\u003e \u003cp\u003e5.8.3 Molecular Epidemiology 140\u003c\/p\u003e \u003cp\u003e5.9 Examples of Tox‐ and Pharm‐Based Experiments Relevant to Signal Transduction Endpoints 140\u003c\/p\u003e \u003cp\u003e5.9.1 Cytotoxicity 141\u003c\/p\u003e \u003cp\u003e5.9.1.1 Nicotine‐Derived Nitrosamine Ketone (NNK) 141\u003c\/p\u003e \u003cp\u003e5.9.1.2 Doxorubicin (DOX) 142\u003c\/p\u003e \u003cp\u003e5.9.1.3 Curcumin 142\u003c\/p\u003e \u003cp\u003e5.9.1.4 Combination Effects of Cisplatin and\/or Leptomycin B (LMB) 143\u003c\/p\u003e \u003cp\u003e5.9.2 DNA Damage 143\u003c\/p\u003e \u003cp\u003e5.9.3 Cell Cycle and Apoptosis 145\u003c\/p\u003e \u003cp\u003e5.9.4 ROS Induction in A549 Cells After LMB and Epigallocatechin Gallate (EGCG) Treatment 146\u003c\/p\u003e \u003cp\u003e5.9.5 Signaling Pathways 146\u003c\/p\u003e \u003cp\u003e5.9.5.1 Metabolizing Alterations After Chemical Exposure 146\u003c\/p\u003e \u003cp\u003e5.9.5.2 p53 Signaling Pathways 148\u003c\/p\u003e \u003cp\u003e5.9.6 Protein Kinase B (Akt\/PKB)\/Mechanistic Target of Rapamycin (mTOR) Pathway Analysis Using Multiblot 150\u003c\/p\u003e \u003cp\u003e5.9.7 Discovery of Unrecognized Pathways\/Molecules Using Proteomics 150\u003c\/p\u003e \u003cp\u003e5.10 Coupling Experimental Results Within the Larger Literature Framework to Generate Information 152\u003c\/p\u003e \u003cp\u003e5.10.1 Cell Proliferation–EGFR Pathway 152\u003c\/p\u003e \u003cp\u003e5.10.2 Cell Cycle 154\u003c\/p\u003e \u003cp\u003e5.10.3 Signal‐Mediated Cell Death 156\u003c\/p\u003e \u003cp\u003e5.10.4 Reactive Oxygen Species (ROS) 161\u003c\/p\u003e \u003cp\u003eReferences 162\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Techniques for Measuring Cellular Signal Transduction 171\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJulie Vrana Miller, Weimin Gao, Meghan Cromie, \u003c\/i\u003eand\u003ci\u003e Zhongwei Liu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 171\u003c\/p\u003e \u003cp\u003e6.2 High‐Throughput Versus High‐Content Data 172\u003c\/p\u003e \u003cp\u003e6.2.1 Ergodic and Nonergodic Systems 173\u003c\/p\u003e \u003cp\u003e6.3 Methods to Measure Signal Transduction Data 173\u003c\/p\u003e \u003cp\u003e6.3.1 Microscopy 173\u003c\/p\u003e \u003cp\u003e6.3.1.1 Widefield Epifluorescence Microscopy 173\u003c\/p\u003e \u003cp\u003e6.3.1.2 Confocal Microscopy 174\u003c\/p\u003e \u003cp\u003e6.3.1.3 Immunohistochemistry 175\u003c\/p\u003e \u003cp\u003e6.3.1.4 FRET 178\u003c\/p\u003e \u003cp\u003e6.3.2 Enzyme‐Linked Immunosorbent Assay (ELISA) 179\u003c\/p\u003e \u003cp\u003e6.3.2.1 Competitive ELISA 179\u003c\/p\u003e \u003cp\u003e6.3.2.2 Sandwich ELISA 180\u003c\/p\u003e \u003cp\u003e6.3.2.3 Direct Cellular ELISA 180\u003c\/p\u003e \u003cp\u003e6.3.2.4 Multiplex Suspension Array Assays 181\u003c\/p\u003e \u003cp\u003e6.3.2.5 Electrochemiluminescence (ECL) Array 182\u003c\/p\u003e \u003cp\u003e6.3.3 Gel Electrophoresis 183\u003c\/p\u003e \u003cp\u003e6.3.4 Western Blot 183\u003c\/p\u003e \u003cp\u003e6.3.5 Protein Nuclear Magnetic Resonance (NMR) 186\u003c\/p\u003e \u003cp\u003e6.4 Techniques to Generate Large Datasets for Signal Transduction Network Analysis 187\u003c\/p\u003e \u003cp\u003e6.4.1 ’‐omics Using Mass Spectrometry 187\u003c\/p\u003e \u003cp\u003e6.4.1.1 Separation Techniques 188\u003c\/p\u003e \u003cp\u003e6.4.1.2 Phosphoprotein Enrichment for Phosphoproteomics: IMAC, MOAC, and SMOAC 189\u003c\/p\u003e \u003cp\u003e6.4.1.3 Quantitation with Chemical Tags: iTRAQ and TMT 190\u003c\/p\u003e \u003cp\u003e6.4.2 RNA Sequencing (RNA‐Seq) 190\u003c\/p\u003e \u003cp\u003e6.5 Bioenergetics 191\u003c\/p\u003e \u003cp\u003e6.5.1 Oxygen Consumption 191\u003c\/p\u003e \u003cp\u003e6.5.2 Reactive Oxygen Species (ROS) Fluorescent Probes 192\u003c\/p\u003e \u003cp\u003e6.5.3 ATP Assays 193\u003c\/p\u003e \u003cp\u003e6.5.4 Nicotinamide Adenine Dinucleotide (NADH) Assay 193\u003c\/p\u003e \u003cp\u003e6.5.5 Mitochondrial Membrane Potential 194\u003c\/p\u003e \u003cp\u003e6.6 Relating Signaling to Cellular Outcome Using Relevant Assays 194\u003c\/p\u003e \u003cp\u003e6.6.1 MTT\/MTS\/WST Assays 194\u003c\/p\u003e \u003cp\u003e6.6.2 LDH Assay 195\u003c\/p\u003e \u003cp\u003e6.6.3 Resazurin Assay (Alamar Blue) 196\u003c\/p\u003e \u003cp\u003e6.6.4 Cell Death: Plasma Membrane Degradation Assay 196\u003c\/p\u003e \u003cp\u003e6.7 Summary 196\u003c\/p\u003e \u003cp\u003eReferences 197\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Computational Methods for Signal Transduction: A Network Approach 201\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eGiovanni Scardoni, Gabriele Tosadori, John Morris, Sakshi Pratap, Carlo Laudanna, \u003c\/i\u003eand\u003ci\u003e Alice Han\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 201\u003c\/p\u003e \u003cp\u003e7.2 Network Construction 203\u003c\/p\u003e \u003cp\u003e7.2.1 Introduction to Network Construction 203\u003c\/p\u003e \u003cp\u003e7.2.2 Network Construction from a Probe 203\u003c\/p\u003e \u003cp\u003e7.2.3 Mapping Methodology 204\u003c\/p\u003e \u003cp\u003e7.2.4 Small Networks 208\u003c\/p\u003e \u003cp\u003e7.2.5 Large Networks 208\u003c\/p\u003e \u003cp\u003e7.3 Facing the Network Analysis 209\u003c\/p\u003e \u003cp\u003e7.3.1 Centralities Definition and Description 211\u003c\/p\u003e \u003cp\u003e7.3.2 Global Parameters 211\u003c\/p\u003e \u003cp\u003e7.3.2.1 Diameter (Δ\u003ci\u003eG\u003c\/i\u003e) 211\u003c\/p\u003e \u003cp\u003e7.3.2.2 Average Distance 212\u003c\/p\u003e \u003cp\u003e7.3.3 Local Parameters 213\u003c\/p\u003e \u003cp\u003e7.3.3.1 Degree 213\u003c\/p\u003e \u003cp\u003e7.3.3.2 Eccentricity 214\u003c\/p\u003e \u003cp\u003e7.3.3.3 Closeness 215\u003c\/p\u003e \u003cp\u003e7.3.3.4 Radiality 215\u003c\/p\u003e \u003cp\u003e7.3.3.5 Centroid Value 217\u003c\/p\u003e \u003cp\u003e7.3.3.6 Stress 219\u003c\/p\u003e \u003cp\u003e7.3.3.7 S.‐P. Betweenness 219\u003c\/p\u003e \u003cp\u003e7.3.3.8 Eigenvector 220\u003c\/p\u003e \u003cp\u003e7.3.3.9 Bridging Centrality 221\u003c\/p\u003e \u003cp\u003e7.3.3.10 Edge Betweenness 221\u003c\/p\u003e \u003cp\u003e7.3.3.11 Normalization and Relative Centralities 222\u003c\/p\u003e \u003cp\u003e7.3.4 Clusters 222\u003c\/p\u003e \u003cp\u003e7.4 Employing Centrality Analysis to Evaluate Stressed Biological Systems 224\u003c\/p\u003e \u003cp\u003e7.5 Interference Notion: How to Perform Virtual Knockout Experiments on Biological Networks 226\u003c\/p\u003e \u003cp\u003e7.5.1 Integrating Experimental Dataset into a Topological Analysis 227\u003c\/p\u003e \u003cp\u003e7.5.2 Integrating Expression or Activation Levels as Nodes Attributes 228\u003c\/p\u003e \u003cp\u003e7.5.3 Edge Attributes as Distance in a Computation 228\u003c\/p\u003e \u003cp\u003e7.6 Network Analysis Software 229\u003c\/p\u003e \u003cp\u003e7.6.1 Cytoscape and Its Apps 229\u003c\/p\u003e \u003cp\u003e7.6.1.1 structureViz\/RINalyzer 231\u003c\/p\u003e \u003cp\u003e7.6.1.2 CentiScaPe 231\u003c\/p\u003e \u003cp\u003e7.6.1.3 PesCa 231\u003c\/p\u003e \u003cp\u003e7.6.1.4 Interference 231\u003c\/p\u003e \u003cp\u003e7.6.1.5 clusterMaker2 232\u003c\/p\u003e \u003cp\u003e7.6.1.6 chemViz 233\u003c\/p\u003e \u003cp\u003e7.6.2 Other Tools 233\u003c\/p\u003e \u003cp\u003e7.6.2.1 Gephi 233\u003c\/p\u003e \u003cp\u003e7.6.2.2 D3.js 234\u003c\/p\u003e \u003cp\u003e7.6.2.3 VisANT 234\u003c\/p\u003e \u003cp\u003e7.7 Conclusions 236\u003c\/p\u003e \u003cp\u003eReferences 236\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 A Toxicological Application of Signal Transduction: Early Cellular Changes Can Be Indicative of Toxicity 239\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJulie Vrana Miller, Nicole Prince, Julia A. Mouch, \u003c\/i\u003eand \u003ci\u003eJonathan W. Boyd\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 239\u003c\/p\u003e \u003cp\u003e8.2 Classification of Toxic Agent and Exposure Effects: A Toxicological Perspective 240\u003c\/p\u003e \u003cp\u003e8.2.1 Dose–Response for Chemical Exposure Toxicity Testing and Risk Assessment 240\u003c\/p\u003e \u003cp\u003e8.2.2 Chemical Mixtures 241\u003c\/p\u003e \u003cp\u003e8.2.3 Mode of Action Versus Mechanism of Action 242\u003c\/p\u003e \u003cp\u003e8.3 Early Cellular Changes Post‐exposure 244\u003c\/p\u003e \u003cp\u003e8.3.1 Intracellular Signaling Perturbations Associated with Exposure 245\u003c\/p\u003e \u003cp\u003e8.3.2 Bioenergetic Changes Post‐exposure 248\u003c\/p\u003e \u003cp\u003e8.3.3 Time Scale of Exposure Effects 249\u003c\/p\u003e \u003cp\u003e8.4 Experimentally Testing Early Cellular Changes that May Contribute to Exposure Sensing and Response 250\u003c\/p\u003e \u003cp\u003e8.4.1 Paradigm Shift Toward \u003ci\u003eIn Vitro\u003c\/i\u003e Cell Culture 250\u003c\/p\u003e \u003cp\u003e8.4.2 Real‐Time \u003ci\u003eIn Vitro\u003c\/i\u003e Assays to Measure Early Cellular Changes 251\u003c\/p\u003e \u003cp\u003e8.4.2.1 Using NADH and Oxygen Consumption to Predict ATP Generation 252\u003c\/p\u003e \u003cp\u003e8.4.3 Prediction of Posttranslational Phosphorylation Response for Mixtures 253\u003c\/p\u003e \u003cp\u003e8.4.3.1 Using Bliss Independence (Response Addition) to Predict Relative Phosphorylation During Critical Signaling Events 253\u003c\/p\u003e \u003cp\u003eReferences 256\u003c\/p\u003e \u003cp\u003eAppendix A 262\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Future Research in Signaling 267\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJonathan W. Boyd, Nicole Prince, \u003c\/i\u003eand\u003ci\u003e Marc Birringer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Translational Research and a Spatiotemporal Understanding of Signal Transduction 267\u003c\/p\u003e \u003cp\u003e9.2 Integrating Second Messengers into Signal Transduction 270\u003c\/p\u003e \u003cp\u003e9.3 Understanding Crosstalk in Signal Transduction 272\u003c\/p\u003e \u003cp\u003e9.4 Posttranslational Modifications (PTMs) and Target Identification in Signal Transduction 274\u003c\/p\u003e \u003cp\u003e9.5 Epigenetic Endpoints in Signal Transduction 276\u003c\/p\u003e \u003cp\u003e9.6 The Integration of Nutrition and Signal Transduction 278\u003c\/p\u003e \u003cp\u003e9.6.1 Cellular AMPK Signaling 281\u003c\/p\u003e \u003cp\u003e9.6.2 Cellular TOR Signaling 282\u003c\/p\u003e \u003cp\u003e9.6.3 Gut Microbiota 282\u003c\/p\u003e \u003cp\u003e9.6.4 The Integration of Endocrine Gut Signaling 283\u003c\/p\u003e \u003cp\u003eReferences 284\u003c\/p\u003e \u003cp\u003eIndex 291\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":48738356101463,"sku":"9781119060260","price":112.46,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119060260.jpg?v=1723811967"},{"product_id":"current-drug-synthesis-9781119847250","title":"Current Drug Synthesis","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e Preface xi \u003cp\u003eContributing Authors xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I Infectious Disease Drugs 1 \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 1 Relebactam (Recarbrio), A β-Lactamase Inhibitor for the Treatment of cIAI\/cUTI\/HABP\/ VABP 3\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 3\u003c\/p\u003e \u003cp\u003e2 Pharmacology 5\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Relationship (SAR) 6\u003c\/p\u003e \u003cp\u003e4 Pharmacokinetics and Drug Metabolism 9\u003c\/p\u003e \u003cp\u003e5 Efficacy and Safety 10\u003c\/p\u003e \u003cp\u003e6 Syntheses 10\u003c\/p\u003e \u003cp\u003e7 Summary 14\u003c\/p\u003e \u003cp\u003e8 References 14\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 2 Vaborbactam (in Combination with Meropenem as Vabomere), a Non-β-Lactam β-Lactamase Inhibitor for Treatment of Complicated Urinary Tract Infections and Pyelonephritis \u003c\/b\u003e\u003cb\u003e17\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 17\u003c\/p\u003e \u003cp\u003e2 Discovery Medicinal Chemistry 21\u003c\/p\u003e \u003cp\u003e3 Vaborbactam\/Vabomere Clinical Trials 27\u003c\/p\u003e \u003cp\u003e4 Vaborbactam Medicinal Chemistry Synthesis 29\u003c\/p\u003e \u003cp\u003e5 Vaborbactam Process Chemistry Synthesis 30\u003c\/p\u003e \u003cp\u003e6 Conclusions 37\u003c\/p\u003e \u003cp\u003e7 References 38\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 3 Baloxavir Marboxil (Xofluza), A Cap-Dependent Endonuclease Inhibitor for Treating Influenza 41 \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 41\u003c\/p\u003e \u003cp\u003e2 Mechanism of Action 43\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Relationship 45\u003c\/p\u003e \u003cp\u003e4 Pharmacokinetics and Drug Metabolism 49\u003c\/p\u003e \u003cp\u003e5 Efficacy and Safety 50\u003c\/p\u003e \u003cp\u003e6 Syntheses 50\u003c\/p\u003e \u003cp\u003e7 Summary 54\u003c\/p\u003e \u003cp\u003e8 References 54\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 4 Process Chemistry Development of the HIV Protease Inhibitor Drug Kaletra: A Mixture of Ritonavir and Lopinavir 57 \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 58\u003c\/p\u003e \u003cp\u003e2 Ritonavir Portion of Kaletra Synthesis 58\u003c\/p\u003e \u003cp\u003e3 Discovery Synthesis of the Ritonavir Core 60\u003c\/p\u003e \u003cp\u003e4 Discovery Synthesis of Ritonavir Wing Pieces 63  \u003c\/p\u003e \u003cp\u003e5 Large-Scale Process Chemistry Synthesis of the  Ritonavir Core 65\u003c\/p\u003e \u003cp\u003e6 Large-Scale Syntheses of the 5-Hydroxymethyl  Thiazole Wing Portion 69\u003c\/p\u003e \u003cp\u003e7 The Large-Scale Coupling of the Thiazole  Wing Pieces to the Core 70\u003c\/p\u003e \u003cp\u003e8 Lopinavir Portion of Kaletra—  Discovery Synthesis and Process Development 72\u003c\/p\u003e \u003cp\u003e9 Discovery Synthesis of Lopinavir 73\u003c\/p\u003e \u003cp\u003e10 Discovery Synthesis of Wing Pieces 74\u003c\/p\u003e \u003cp\u003e11 Process Improvements to the Wing Pieces 76\u003c\/p\u003e \u003cp\u003e12 Optimization of Lopinavir Synthesis with Intermediates 78\u003c\/p\u003e \u003cp\u003e13 Conclusions 81\u003c\/p\u003e \u003cp\u003e14 References 81\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 5 Eravacycline (Xerava), A Novel and Completely Synthetic Fluorocycline Antibiotic 85 \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 85\u003c\/p\u003e \u003cp\u003e2 Pharmacology 89\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Relationship (SAR) 91\u003c\/p\u003e \u003cp\u003e4 Pharmacokinetics and Drug Metabolism 93\u003c\/p\u003e \u003cp\u003e5 Efficacy and Safety 93\u003c\/p\u003e \u003cp\u003e6 Syntheses 93\u003c\/p\u003e \u003cp\u003e7 Summary 98\u003c\/p\u003e \u003cp\u003e8 References 99\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 6 Albuvirtide (Aikening), A gp41 Analog as an HIV-1 Fusion Inhibitor 101 \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 101\u003c\/p\u003e \u003cp\u003e2 Pharmacology 102\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Relationship (SAR) 106\u003c\/p\u003e \u003cp\u003e4 Pharmacokinetics and Drug Metabolism 107\u003c\/p\u003e \u003cp\u003e5 Efficacy and Safety 110\u003c\/p\u003e \u003cp\u003e6 Syntheses 112\u003c\/p\u003e \u003cp\u003e7 Summary 114\u003c\/p\u003e \u003cp\u003e8 References 115\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II Cancer Drugs 119 \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 7 Darolutamide (Nubeqa): An Androgen Receptor  Antagonist for Treating Nonmetastatic, Castration-Resistant 121 \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 121\u003c\/p\u003e \u003cp\u003e2 Pharmacology 124\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Relationship (SAR) 126\u003c\/p\u003e \u003cp\u003e4 Pharmacokinetics and Drug Metabolism 132\u003c\/p\u003e \u003cp\u003e5 Efficacy and Safety 134\u003c\/p\u003e \u003cp\u003e6 Syntheses 135\u003c\/p\u003e \u003cp\u003e7 The Future 137\u003c\/p\u003e \u003cp\u003e8 References 138\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 8 Venetoclax (Venclexta): A BCL-2 Antagonist for Treating Chronic Lymphocytic Leukemia 143 \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 143\u003c\/p\u003e \u003cp\u003e2 Pharmacology 144\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Relationship (SAR) 147\u003c\/p\u003e \u003cp\u003e4 Pharmacokinetics and Drug Metabolism 153\u003c\/p\u003e \u003cp\u003e5 Efficacy and Safety 154\u003c\/p\u003e \u003cp\u003e6 Syntheses 155\u003c\/p\u003e \u003cp\u003e7 Summary 160\u003c\/p\u003e \u003cp\u003e8 References 161\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 9 Osimertinib (Tagrisso), A Potent and Selective Third-Generation EGFR Inhibitor for the Treatment of Both Sensitizing and T790M-Resistance Mutations 165 \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 165\u003c\/p\u003e \u003cp\u003e2 Pharmacology 167\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Relationship (SAR) 170\u003c\/p\u003e \u003cp\u003e4 Pharmacokinetics and Drug Metabolism 173\u003c\/p\u003e \u003cp\u003e5 Efficacy and Safety 174\u003c\/p\u003e \u003cp\u003e6 Syntheses 175\u003c\/p\u003e \u003cp\u003e7 Summary 180\u003c\/p\u003e \u003cp\u003e8 References 180\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 10 Sotorasib (LUMAKRA), An Irreversible Covalent Inhibitor of KRASG12C 183 \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 183\u003c\/p\u003e \u003cp\u003e2 Pharmacology 184\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Relationship (SAR) 186\u003c\/p\u003e \u003cp\u003e4 Pharmacokinetics and Drug Metabolism 191\u003c\/p\u003e \u003cp\u003e5 Efficacy and Safety 191\u003c\/p\u003e \u003cp\u003e6 Syntheses 192\u003c\/p\u003e \u003cp\u003e7 Summary 196\u003c\/p\u003e \u003cp\u003e8 References 196\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 11 Lorlatinib (Lorbrena), An ALK Inhibitor for Treating NSCLC 201 \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 201\u003c\/p\u003e \u003cp\u003e2 Pharmacology 203\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Relationship (SAR) 205\u003c\/p\u003e \u003cp\u003e4 Pharmacokinetics and Drug Metabolism 210\u003c\/p\u003e \u003cp\u003e5 Efficacy and Safety 211\u003c\/p\u003e \u003cp\u003e6 Syntheses 213\u003c\/p\u003e \u003cp\u003e7 Summary 226\u003c\/p\u003e \u003cp\u003e8 References 227\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 12 Niraparib (Zejula) A Small Molecule, PARP1\/2 Inhibitor for Treating Breast, Ovarian, and Pancreatic Cancers 231\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2 Pharmacology 235\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Relationship (SAR) 238\u003c\/p\u003e \u003cp\u003e4 Pharmacokinetics and Drug Metabolism 243\u003c\/p\u003e \u003cp\u003e5 Efficacy and Safety 243\u003c\/p\u003e \u003cp\u003e6 Syntheses 244\u003c\/p\u003e \u003cp\u003e7 Summary 248\u003c\/p\u003e \u003cp\u003e8 References 248\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 13 Selinexor (Xpovio), An XPO1 Inhibitor and a New Class of Therapeutics for Treating Multiple Myeloma 253\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Exportin1 (XPO1) 253\u003c\/p\u003e \u003cp\u003e2 Overview of Multiple Myeloma 255\u003c\/p\u003e \u003cp\u003e3 Development of Selinexor 256\u003c\/p\u003e \u003cp\u003e4 Pharmacology and Mechanism 257\u003c\/p\u003e \u003cp\u003e5 Pharmacokinetics, Pharmacodynamics and Drug Metabolism 258\u003c\/p\u003e \u003cp\u003e6 Efficacy and Safety 259\u003c\/p\u003e \u003cp\u003e7 Syntheses 259\u003c\/p\u003e \u003cp\u003e8 Summary and Future 262\u003c\/p\u003e \u003cp\u003e9 References 262\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III Cns Drugs 265\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 14 Sage 217 (Zuranolone) for Treating Major of Depressive Disorder267\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 267\u003c\/p\u003e \u003cp\u003e2 Pharmacology 270\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Relationship (SAR) 272\u003c\/p\u003e \u003cp\u003e4 Pharmacokinetics and Drug Metabolism 279\u003c\/p\u003e \u003cp\u003e5 Efficacy and Safety 280\u003c\/p\u003e \u003cp\u003e6 Syntheses 281\u003c\/p\u003e \u003cp\u003e7 Summary 282\u003c\/p\u003e \u003cp\u003e8 References 283\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 15 Risdiplam (Evrysdi), A Small Molecule, SMN2-directed RNA Splicing Modifier for Treating Spinal Muscular Atrophy 287\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 287\u003c\/p\u003e \u003cp\u003e2 Pharmacology 289\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Relationship (SAR) 290\u003c\/p\u003e \u003cp\u003e4 Pharmacokinetics and Drug Metabolism 297\u003c\/p\u003e \u003cp\u003e5 Efficacy and Safety 297\u003c\/p\u003e \u003cp\u003e6 Syntheses 298\u003c\/p\u003e \u003cp\u003e7 Summary 300\u003c\/p\u003e \u003cp\u003e8 References 301\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV Miscellaneous Drugs 305\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 16 Esaxerenone (Minnebro), An Oral, Non-steroidal, Selective Mineralocorticoid Receptor Blocker for the Treatment of Essential Hypertension307\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 307\u003c\/p\u003e \u003cp\u003e2 Pharmacology 310\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Relationship (SAR) 311\u003c\/p\u003e \u003cp\u003e4 Pharmacokinetics and Drug Metabolism 313\u003c\/p\u003e \u003cp\u003e5 Efficacy and Safety 315\u003c\/p\u003e \u003cp\u003e6 Syntheses 316\u003c\/p\u003e \u003cp\u003e7 Summary 320\u003c\/p\u003e \u003cp\u003e8 References 321\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 17 Voclosporin (Lupkynis), A Macrocyclic Peptide Inhibitor of Calcineurin for the Treatment of Lupus Nephritis 323\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 323\u003c\/p\u003e \u003cp\u003e2 Pharmacology 326\u003c\/p\u003e \u003cp\u003e3 Structure–Activity Relationship (SAR) 326\u003c\/p\u003e \u003cp\u003e4 Pharmacokinetics and Drug Metabolism 329\u003c\/p\u003e \u003cp\u003e5 Efficacy and Safety 331\u003c\/p\u003e \u003cp\u003e6 Syntheses 333\u003c\/p\u003e \u003cp\u003e7 References 336\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 18 Computational-Aided Drug Design 339\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Background 339\u003c\/p\u003e \u003cp\u003e2 Structure-based Drug Design (SBDD) 341\u003c\/p\u003e \u003cp\u003e3 Ligand-based Drug Design (LBDD) 352\u003c\/p\u003e \u003cp\u003e4 Summary 361\u003c\/p\u003e \u003cp\u003e5 References 362\u003c\/p\u003e \u003cp\u003eIndex 373\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":48738370617687,"sku":"9781119847250","price":126.35,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119847250.jpg?v=1723811987"},{"product_id":"chiroptical-spectroscopy-9781420092462","title":"Chiroptical Spectroscopy","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis book details chiroptical spectroscopic methods: electronic circular dichroism (ECD), optical rotatory dispersion (ORD), vibrational circular dichroism (VCD), and vibrational Raman optical activity (VROA). For each technique, the text presents experimental methods for measurements and theoretical methods for analyzing the experimental data. It also includes a set of experiments that can be adopted for undergraduate teaching laboratories. Each chapter is written in an easy-to-follow format for novice readers, with necessary theoretical formalism in appendices for advanced readers. \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003ePolarized Light; Chiral Molecules; Interaction of Circularly Polarized Light with Chiral Molecules; Quantum Chemical Formulation of Chiroptical Spectroscopy; Prediction of Chiroptical Spectra; Conformational Analysis; Experimental Methods for Measuring Chiroptical Spectra; Comparison of Experimental and Calculated Spectra; Chiral Aggregation, Equilibria and the Horeau effect; Applications of Chiroptical Spectra\u003c\/p\u003e","brand":"Taylor \u0026 Francis Inc","offers":[{"title":"Default Title","offer_id":48739127001431,"sku":"9781420092462","price":175.75,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781420092462.jpg?v=1720051247"},{"product_id":"say-why-to-drugs-9781473686229","title":"Say Why to Drugs","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eA definitive and authoritative guide to drugs and why we're all hooked from the presenter of the top-rated podcast, Say Why to Drugs.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003eEssential * Adam Rutherford *","brand":"Hodder \u0026 Stoughton","offers":[{"title":"Default Title","offer_id":48739549020503,"sku":"9781473686229","price":16.14,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781473686229.jpg?v=1723812243"},{"product_id":"medical-science-in-the-21st-century-sunset-or-new-dawn-9781848169548","title":"Medical Science In The 21st Century: Sunset Or","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis book sets out the unique and paradoxical position biomedical science finds itself in, in the early 21st (superscript st) century. Science has never been stronger in shaping the world we live in; progress in medical science during most of the last century has helped to transform health care and prolong our lives; almost daily advances in biological science promise hope for the future and yet medical science has been in serious decline for the past three decades.Biomedical Science in the 21st (superscript st) Century: Sunset or New Dawn? sets out the recent decline in the context of medical science's stunning past successes. Professor Sheridan discusses the failure to translate new discoveries in biological science into medical advances; the dramatic decline in research productivity in the pharmaceutical industry in the context of falling numbers of clinical scientists; the disruption of medical science during prolonged and repeated reforms of health care delivery; changing social and political attitudes towards health care and science; the loss of trust in big pharmaceutical companies and recent revelations of fraud in science. The book deals with the creative nature of original science, how it is driven by curiosity and self-motivation and how these can be stifled by pettifogging managerialism.The book presents a vision of what medical science can deliver during the coming half century and what is needed to overcome the present challenges. It questions the assumptions that big is best in the organisation of science and suggests a new model for drug development based on a restoration of trust and a more constructive relationship between regulators and industry.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eThe Rise and Fall of Medical Science in the 20th Century; Advances in Medicine: How Are They Made?; The Impact of the Changing Social, Political and Economic Environment on Medical Science; Fraud in Biomedical Science; The Decline of Biomedical Science Despite Unprecedented Technological Advances: A 21st Century Paradox; Changes in Medical Professionalism in the 21st Century and Their Impact on Medical Science; The Global Demographic Challenge: The Role of Medical Science; Biomedical Science in Modern Economies: Innovation and Health; The Centrality of Medical Science in the 21st Century: Protecting Health and Meeting Future Economic Challenges.","brand":"Imperial College Press","offers":[{"title":"Default Title","offer_id":48742234653015,"sku":"9781848169548","price":45.6,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781848169548.jpg?v=1720060574"},{"product_id":"bartrams-encyclopedia-of-herbal-medicine-9781854875860","title":"Bartram's Encyclopedia of Herbal Medicine","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eContaining over 900 entries of general disease conditions and corresponding herbal treatments, this book covers: therapeutic action, 550 monographs of medicinal plants, and the properties of herbs and preparations such as inctures, liquid extracts, poultices and essential oils.","brand":"Little, Brown Book Group","offers":[{"title":"Default Title","offer_id":48742331253079,"sku":"9781854875860","price":14.24,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781854875860.jpg?v=1720060962"},{"product_id":"pharmacology-case-studies-for-nurse-prescribers-9781910451250","title":"Pharmacology Case Studies for Nurse Prescribers","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e","brand":"M\u0026K Update Ltd","offers":[{"title":"Default Title","offer_id":48742561677655,"sku":"9781910451250","price":42.75,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781910451250.jpg?v=1720061914"},{"product_id":"drug-science-and-british-drug-policy-critical-analysis-of-the-misuse-of-drugs-act-1971-9781914603266","title":"Drug Science and British Drug Policy: Critical","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eFor half a century the Misuse of Drugs Act 1971 has dominated ill-conceived approaches to the prohibition of drugs and the criminalisation of many offenders. Wilful blindness to scientific facts has distorted the dispensation of justice, prevented lifesaving investigation, sidelined critics and thwarted advocates of politically inconvenient drugs law reform. This once in an epoch review by experts from a range of disciplines shows how lawmakers and the media have ignored the scientific evidence to sustain badly founded rhetoric in favour of blanket bans, punishment and the marginalisation of opponents. Countless individuals (including the vulnerable, deprived, addicted and mentally ill) have therefore suffered unnecessarily. This, the most comprehensive critique of the 1971 Act yet, rests on the combined learning of leading medical, scientific, psychiatric, academic, legal, drug safety and other specialists to provide sound reasons to re-think half a century of bad law.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e'It is time to see the MDA 1971 for what it is: a bad law that has the opposite effect to that intended. The so-called war on drugs is lost. It could never be won. Let us replace this knee-jerk law with something rational, something evidence-based, something more humane.'- From the Foreword.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eForeword by The Rt Hon Norman Baker; Introduction. PART I - The Impact Of Drugs: At the Frontiers of Psychiatry; A Forensic Science Perspective; Fifty Years of MDMA; Displacement, Adulteration and Innovation - How the MDA 1971 Failed to Control NPS; Cannabis: Past, Present and Future; Narratives of Drug-related Harm. PART II - Impact on the Medical, Pharmacy and Veterinary Professions: Chronic Pain; The Impact of the MDA 1971 on the Veterinary Profession; Enabling Access to Essential Medicines and Devices. PART III - Legacies of the Drug Laws: How States Have Adapted Their Drug Laws; The Sixties, Barbara Wootton and the Counterculture - Revisiting the Origins of the MDA 1971; The Ongoing Impact on the Racialised Policing of Black Communities. PART IV - Perspectives and Approaches: Challenging Stigma, Changing Minds; The MDA 1971: No Education; The Impact of Drug Legislation on Climate Change; Decision Conferencing and Multi-criteria Decision Analysis; The MDA 1971: Missteps and Misunderstandings. PART V - Changing Policy: Regulating the Legal: Lessons from Alcohol Policy and the Battle for Minimum Unit Pricing in Scotland; A Modest Proposal to Decriminalise the Simple Possession of Drugs; The Legal Regulation of Drugs in the UK. Index.","brand":"Waterside Press","offers":[{"title":"Default Title","offer_id":48742787219799,"sku":"9781914603266","price":23.75,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781914603266.jpg?v=1720062824"},{"product_id":"human-challenge-studies-in-endemic-settings-ethical-and-regulatory-issues-9783030414795","title":"Human Challenge Studies in Endemic Settings:","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThis open access book provides an extensive review of ethical and regulatory issues related to human infection challenge studies, with a particular focus on the expansion of this type of research into endemic settings and\/or low- and middle-income countries (LMICs). Human challenge studies (HCS) involve the intentional infection of research participants, and this type of research is rapidly increasing in frequency worldwide. HCS are widely considered to be an especially promising approach to vaccine development, including for pathogens endemic to LMICs. However, challenge studies are sometimes controversial and raise complex ethical issues, some of which are especially salient in endemic and\/or LMIC settings. Informed by qualitative interviews with experts in infectious diseases and bioethics, this book highlights areas of ethical consensus and controversy concerning this kind of research. As the first volume to focus on ethical issues associated with human challenge studies, it sets the agenda for further work in this important area of global health research; contributes to current debates in research ethics; and aims to inform regulatory policy and research practice.  Insofar as it focuses on HCS in (endemic) settings where diseases are present and\/or widespread, much of the analysis provided here is directly relevant to HCS involving pandemic diseases including COVID19. \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1. Introduction.- 2. Methods.- 3. History of human challenge studies.- 4. ethical issues.- 5. Community engagement, ethics review, and regulation.- 6. Case studies.- 7. Conclusions.- Acknowledgements. ","brand":"Springer Nature Switzerland AG","offers":[{"title":"Default Title","offer_id":48743035535703,"sku":"9783030414795","price":13.49,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783030414795.jpg?v=1720063827"},{"product_id":"principles-of-forensic-toxicology-9783030429164","title":"Principles of Forensic Toxicology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThe fifth edition of the best-selling Principles in Forensic Toxicology continues in the tradition of excellence in academic publishing. With over 10 years of classroom-tested and continually updated content, the new edition contains significant updates and 7 new chapters on new topics including drug-facilitated crimes, derivatization, quantitation, measurement uncertainty\/traceability, statistics, oral fluid testing, and drugs in embalmed specimens. Part One covers the major sub-disciplines of forensic toxicology in addition to pharmacological concepts. Part Two addresses specimen preparation, laboratory testing and instrumental analysis, while Part Three discusses common analytes including cocaine, opioids, alcohol, and marijuana.  Adopted  for courses in many of the top universities for forensic science and used by respected medical examiner’s offices and crime laboratories worldwide, \u003ci\u003ePrinciples of Forensic Toxicology\u003c\/i\u003e prepares the next generation of forensic toxicologists and continues to be an important reference in professional practice.\u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003cbr\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePart 1: Introduction.- Post Mortem Forensic Toxicology.- Human Performance Toxicology.- Drug-Facilitated Sexual Assault.- Forensic Drug Testing.- Performance enhancing Drug Testing.- Drug Testing in Pain Management.- Pharmacokinetics and Pharmacodynamics.- Part II. Specimen Preparation.- Spectrophotometry.- Chromatography.- Derivatization.- Immunoassy.- Mass Spectrometry.- Quantitation.- Method Validation.- Measurement Uncertainty and Traceability.- Statistics in Forensic Toxicology.- Part III Analytes.- Alcohol.- Benzodiazapines.- Gammahydroxybutyric acid,- Miscellaneous Central Nervous System Depressants.- Opioids.- Cocanie.- Cannabis.- Amphetamines-Sympathomimetic Amines,- Hallucinogens and Psychedelics.- Antidepressants and Neuroleptics.- Miscellaneous Therapeutic Drugs.- Carbon Monoxide\/Cyanide.- Inhalants.- Metals.- Part III Special Topics.- Stability of Drugs of Abuse in Biological Systems.- Postmortem Redistribution of Drugs.- Postmortem Clinical Testing.- Pharmacogenomics.- Hair Drug Testing.- Oral Fluid Testing.- Meconium Drug Testing.- Drugs in Embalmed Tissues.","brand":"Springer Nature Switzerland AG","offers":[{"title":"Default Title","offer_id":48743035863383,"sku":"9783030429164","price":61.74,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783030429164.jpg?v=1720063827"},{"product_id":"cannabis-laboratory-fundamentals-9783030627157","title":"Cannabis Laboratory Fundamentals","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThe legislative requirement for cannabis to undergo laboratory testing has followed legalization of medical and recreational use in every U.S. state to date.  Cannabis safety testing is a new investment opportunity within the emerging cannabis market that is separate from cultivation, processing, and distribution, allowing individuals and organizations who may have been reluctant to enter previously a new entry route to the cannabis space. However, many of the costs, timelines, operational requirements, and compliance issues are overlooked by people who have not been exposed to regulated laboratory testing.\u003c\/p\u003e  \u003cp\u003eCannabis Laboratory Fundamentals provides an in-depth review of the key issues that impact cannabis testing laboratories and provides recommendations and solutions to avoid common – but expensive – mistakes. The text goes beyond methodology to include sections on economics, regulation, and operational challenges, making it useful for both new and experienced cannabis laboratory operators, as well as all those who want to understand the opportunities and risks of this industry.\u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e1.       An Introduction to Cannabis Laboratory Safety and Compliance Testing\u003c\/p\u003e  \u003cp\u003e2.       Cannabis Safety Testing Laboratory Floor Planning \u0026amp; Design\u003c\/p\u003e  \u003cp\u003e3.       Laboratory Safety from Site Selection to Daily Operation\u003c\/p\u003e  \u003cp\u003e4.       Preparing Cannabis Laboratory Business License Applications\u003c\/p\u003e  \u003cp\u003e5.       Quality Assurance and the Cannabis Analytical Laboratory\u003c\/p\u003e  \u003cp\u003e6.       Cannabis Laboratory Management: Staffing, Training and Quality\u003c\/p\u003e  \u003cp\u003e7.       Laboratory Information Management Systems (LIMS)\u003c\/p\u003e  \u003cp\u003e8.       Pesticide and Mycotoxin Detection and Quantitation\u003c\/p\u003e  \u003cp\u003e9.       Cannabinoid Detection and Quantitation\u003c\/p\u003e  \u003cp\u003e10.   Utilizing GC-MS and GC Instrumentation for Residual Solvents in Cannabis and Hemp\u003c\/p\u003e  \u003cp\u003e11.   Elemental Analysis of Cannabis and Hemp – Regulations, Instrumentation, and Best Practices\u003c\/p\u003e  \u003cp\u003e12.   Quantitative Terpene Profiling from Cannabis Samples\u003c\/p\u003e  \u003cp\u003e13.   Laboratory Safety and Compliance Testing for Microorganism Contamination in Marijuana\u003c\/p\u003e","brand":"Springer Nature Switzerland AG","offers":[{"title":"Default Title","offer_id":48743042941271,"sku":"9783030627157","price":71.24,"currency_code":"GBP","in_stock":true}]},{"product_id":"principles-and-practices-of-lyophilization-in-product-development-and-manufacturing-9783031126338","title":"Principles and Practices of Lyophilization in","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThe biotechnology\/biopharmaceutical sector has tremendously grown which led to the invention of engineered antibodies such as Antibody Drug Conjugates (ADCs), Bispecific T cell engager ( BITES), Dual Variable Domain ( DVD), Chimeric Antigen Receptor  - Modified Tcells (CART) that are currently being used as therapeutic agents for immunology and oncology disease conditions.  In addition to other pharmaceuticals and biopharmaceuticals, all these novel formats are fragile with respect to  their stability\/structure under processing conditions meaning marginal stability in the liquid state and often require lyophilization to enhance their stability and shelf-life. This book contains chapters\/topics that will describe every aspect of the lyophilization process and product development and manufacturing starting from the overview of lyophilization process, equipment required, characterization of the material, design and development of the formulation and lyophilization process, various techniques for\u003cb\u003e \u003c\/b\u003echaracterization of the product, scale-up\/tech-transfer and validation.  It also describes the application of CFD coupled with mathematical modeling in the lyophilization process and product development, scale-up, and manufacturing.  Additionally, \u003ci\u003ePrinciples and Practice of Lyophilization Process and Product Development\u003c\/i\u003e contains an entire dedicated section on “Preservation of Biologicals” comprised of nine chapters written by experts and including case studies.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1. Overview of Freeze Drying\u003cbr\u003e2. Characterization and Determination of Freeze Drying Properties of Frozen Formulations- Case Studies\u003cbr\u003e3. Beyond pH: Acid\/base relationships in frozen and freeze-dried pharmaceuticals\u003cbr\u003e4. Concepts and Strategies in the Design of Formulation for Freeze Drying\u003cbr\u003e5. Formulation Design for Freeze Drying - Case studies of Stabilization of Proteins\u003cbr\u003e6. Challenges and Considerations in the Development of a High Protein Concentration Lyophilized Drug Product\u003cbr\u003e7. Freeze-drying of thermosensible pharmaceuticals with organic co-solvent + water formulations\u003cbr\u003e8. Primary container closure system selection for lyophilized drug products\u003cbr\u003e9. Vial Breakage During Lyophilization\u003cbr\u003e10. The Nucleation of Ice\u003cbr\u003e11. Stresses, Stabilization, and Recent Insights in Freezing of Biologics\u003cbr\u003e12. Lyophilization Process Understanding and Scale-up using ab initio Vial Heat Transfer Modeling\u003cbr\u003e13. Secondary drying: Challenges and Considerations\u003cbr\u003e14. Design and Process Considerations in Spray Freeze Drying\u003cbr\u003e15. LyoPRONTO: Deterministic and Probabilistic Modeling. Tutorial and Case Study\u003cbr\u003e16. Utilizing Solid-State NMR Spectroscopy to Assess Properties of Lyophilized Formulations\u003cbr\u003e17. Design of Moisture Studies for a Lyophilized Product\u003cbr\u003e18. Laser-Based Headspace Moisture Analysis for Rapid Nondestructive Moisture Determination of Lyophilized Products\u003cbr\u003e19. Application of PAT in Real-time Monitoring and Controlling of Lyophilization Process\u003cbr\u003e20. Process Analytical Technology (PAT) for Lyophilization Process Monitoring and End Point Detection\u003cbr\u003e21. Advances in Process Analytical Technology – A Small Scale Freeze-Dryer for Process Analysis, Optimization, and Transfer Advances in Process Analytical Technology – A Small Scale Freeze-Dryer for Process Analysis, Optimization, and Transfer\u003cbr\u003e22. Overview of Heat and Mass Transfer Modeling in Lyophilization to Create Design Spaces and Improve Process Analytical Tool (PAT) Capability\u003cbr\u003e23. Application of QbD elements in the Development and Manufacturing of a Lyophilized product.- Characterization of Freeze Dryer\u003cbr\u003e24. Characterization of Freeze Dryer\u003cbr\u003e25. Scale-up and Technology Transfer of a Lyophilization Process\u003cbr\u003e26.  Lyophilization Validation: Process Design and Modeling\u003cbr\u003e27. Lyophilization Validation: Process Qualification and Continued Process Verification\u003cbr\u003e28. Homogeneity Assessment of Lyohilized Biological Drug Products During Process Performance Qualification\u003cbr\u003e29. Informed Manufacturing through the use of Big Data Analytics for Freeze Drying Process \u0026amp; Equipment\u003cbr\u003e30. Multivariate Analysis for Process Understanding, Continuous Process Verification and Condition Monitoring of Lyophilization Processes\u003cbr\u003e31.  Lyophilized Drug Product Cake Appearance: What Is Acceptable?\u003cbr\u003e​","brand":"Springer International Publishing AG","offers":[{"title":"Default Title","offer_id":48743071646039,"sku":"9783031126338","price":999.99,"currency_code":"GBP","in_stock":false}]},{"product_id":"apicomplexan-parasites-molecular-approaches-toward-targeted-drug-development-9783527327317","title":"Apicomplexan Parasites: Molecular Approaches","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis handbook is the first dealing with the discovery of drugs directed against apicomplexan parasites. Amongst others, this group of endoparasites includes the causative agents  of Malaria, Toxoplasmosis, and Babesiosis, the latter occurring mainly in animals. Written by renowned scientific experts from academia and industry, the book focuses on currentdrug development approaches for all apicomplexan diseases making it appealing to a large audience, ranging from research labs in academia to the human and veterinarian pharmaceutical industry. This work is the second volume of the new book series 'Drug Discovery in Infectious Diseases', edited by Prof. Dr Paul M. Selzer.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eSCREENING, BIOINFORMATICS, CHEMOINFORMATICS, AND DRUG DESIGN\u003cbr\u003e Drug Discovery Approaches towards Anti-Parasitic Agents \u003cbr\u003e (Andreas Rohwer, Richard J. Marhofer, Conor R. Caffrey and Paul M. Selzer)\u003cbr\u003e New Bioinformatic Strategies against Apicomplexan Parasites\u003cbr\u003e (Thomas Dandekar and Ke Xiao)\u003cbr\u003e Sorting Potential Therapeutic Targets in Apicomplexa\u003cbr\u003e (Jan A. Hiss and Gisbert Schneider)\u003cbr\u003e \u003cbr\u003e Alternatives to Drug Development in Apicomplexa\u003cbr\u003e (Prof. Dr. Theo P.M. Schetters)\u003cbr\u003e \u003cbr\u003e METABOLIC PATHWAYS AND PROCESSES ADDRESSED BY CURRENT DRUG DISCOVERY APPROACHES\u003cbr\u003e \u003cbr\u003e The Energy Metabolism as an Antimalarial Drug Target\u003cbr\u003e (Esther Jortzik and Katja Becker)\u003cbr\u003e Polyamines in Apicomplexan Parasites\u003cbr\u003e (Ingrid B. Muller, Robin Das Gupta, Kai Luersen, Carsten Wrenger and Rolf D. Walter)\u003cbr\u003e The Reducing Milieu of Parasitized Cells as a Target of Antimalarial Agents. Methylene Blue as an Ethical Drug\u003cbr\u003e (Peter Meissner, Heike Adler, Karin Fritz-Wolf and R. Heiner Schirmer)\u003cbr\u003e Lipids as Drug Targets for Malaria Therapy\u003cbr\u003e (Henri J. Vial, Diana Penarete, Sharon Wein, Sergio Caldarelli, Laurent Fraisse and Suzanne Peyrottes)\u003cbr\u003e Targeting Apicoplast Pathways in Plasmodium\u003cbr\u003e (Snober S. Mir, Subir Biswas and Saman Habib)\u003cbr\u003e Lipoic Acid Acquisition and Glutathione Biosynthesis in Apicomplexan Parasites\u003cbr\u003e (Janet Storm, Eva-Maria Patzewitz and Sylke Muller)\u003cbr\u003e Antimalarial Drugs and Molecules Inhibiting Hemozoin formation\u003cbr\u003e (Uday Bandyopadhyay and Sumanta Dey)\u003cbr\u003e Exploiting the Vitamin Metabolism of Apicomplexa as Drug Targets\u003cbr\u003e (Carsten Wrenger and Ingrid B. Muller)\u003cbr\u003e \u003cbr\u003e Vitamin Biosynthetic Pathways, the PLP Synthase Complex, and the Potential for Drugging Protein-Protein Interaction\u003cbr\u003e (Ivo Tews and Irmgard Sinning)\u003cbr\u003e Targeting Prokaryotic Enzymes in the Eukaryotic Pathogen Cryptosporidium\u003cbr\u003e (Suresh Kumar Gorla, Corey Johnson, Jihan Khan, Xin Sun, Lisa Sharling,\u003cbr\u003e Boris Striepen and Lizbeth Hedstrom)\u003cbr\u003e \u003cbr\u003e DRUG TARGETS IN APICOMPLEXAN PARASITES \u003cbr\u003e Novel Apicomplexan Phosphatases and Immunophilins \u003cbr\u003e as Domain-Specific Drug Targets\u003cbr\u003e (Sailen Barik)\u003cbr\u003e Dehydrogenases and enzymes of the mitochondrial electron transport chain as antiapicomplexan drug targets\u003cbr\u003e (Kathleen Zocher, Stefan Rahlfs and Katja Becker)\u003cbr\u003e Calcium-dependent protein kinases as drug targets in apicomplexan parasites\u003cbr\u003e (Dominik Kugelstadt, Bianca Derrer, and Barbara Kappes)\u003cbr\u003e \u003cbr\u003e \u003cbr\u003e Protein Acylation:\u003cbr\u003e New Potential Targets for Intervention against Apicomplexa\u003cbr\u003e (Joana M. Santos, Christian Hedberg and Dominique Soldati-Favre)\u003cbr\u003e Drugs and Drug Targets in Neospora Caninum and Related Apicomplexans\u003cbr\u003e (Joachim Muller, Norbert Muller and Andrew Hemphill)\u003cbr\u003e \u003cbr\u003e COMPOUNDS \u003cbr\u003e Subversive Substrates of Glutathione Reductases from P. Falciparum-infected Red Blood Cells as Antimalarial Agents\u003cbr\u003e (Elisabeth Davioud-Charvet and Don Antoine Lanfranchi)\u003cbr\u003e Ferroquine: a Concealed Weapon (Christophe Biota, Bruno Pradinesb and Daniel Divec)\u003cbr\u003e \u003cbr\u003e Current Aspects of Endoperoxides in Antiparasitic Chemotherapy\u003cbr\u003e (Denis Matovu Kasozi, Stefan Rahlfs and Katja Becker)\u003cbr\u003e \u003cbr\u003e Plasmodium Hsp90 as an Antimalarial Target\u003cbr\u003e (G. Sridhar Prasad and Sailen Barik)\u003cbr\u003e Drug Discovery against Babesia and Toxoplasma\u003cbr\u003e (Mohamad Alaa Terkawi and Ikuo Igarashi)\u003cbr\u003e Search for Drugs and Drug Targets against Babesia bovis, Babesia bigemina, Babesia caballi, and Babesia (Theileria) equi\u003cbr\u003e (Sabine Bork-Mimm)\u003cbr\u003e Orlistat: A Repositioning Opportunity as a Growth Inhibitor of Apicomplexan Parasites?\u003cbr\u003e (Christian Miculka, Hon Tran, Thorsten Meyer, Anja R. Heckeroth, Stefan Baumeister, Frank Seeber and Paul M. Selzer)\u003cbr\u003e Recent drug discovery against Cryptosporidium\u003cbr\u003e (Jean-Francois Rossignol, Gilles Gargala, J. Edward Semple and Andrew V. Stachulski)\u003cbr\u003e \u003cbr\u003e","brand":"Wiley-VCH Verlag GmbH","offers":[{"title":"Default Title","offer_id":48743116734807,"sku":"9783527327317","price":999.99,"currency_code":"GBP","in_stock":false}]},{"product_id":"computational-drug-discovery-2-volumes-methods-and-applications-9783527351664","title":"Computational Drug Discovery, 2 Volumes: Methods","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eComputational Drug Discovery\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eA comprehensive resource that explains a wide array of computational technologies and methods driving innovation in drug discovery\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eComputational Drug Discovery: Methods and Applications\u003c\/i\u003e (2 volume set) covers a wide range of cutting-edge computational technologies and computational chemistry methods that are transforming drug discovery. The book delves into recent advances, particularly focusing on artificial intelligence (AI) and its application for protein structure prediction, AI-enabled virtual screening, and generative modeling for compound design. Additionally, it covers key technological advancements in computing such as quantum and cloud computing that are driving innovations in drug discovery.\u003c\/p\u003e \u003cp\u003eFurthermore, dedicated chapters that addresses the recent trends in the field of computer aided drug design, including ultra-large-scale virtual screening for hit identification, computational strategies for designing new therapeutic modalities like PROTACs and covalent inhibitors that target residues beyond cysteine are also presented.\u003c\/p\u003e \u003cp\u003eTo offer the most up-to-date information on computational methods utilized in \u003ci\u003eComputational Drug Discovery,\u003c\/i\u003e it covers chapters highlighting the use of molecular dynamics and other related methods, application of QM and QM\/MM methods in computational drug design, and techniques for navigating and visualizing the chemical space, as well as leveraging big data to drive drug discovery efforts.\u003c\/p\u003e \u003cp\u003eThe book is thoughtfully organized into eight thematic sections, each focusing on a specific computational method or technology applied to drug discovery. Authored by renowned experts from academia, pharmaceutical industry, and major drug discovery software providers, it offers an overview of the latest advances in \u003ci\u003ecomputational drug discovery\u003c\/i\u003e.\u003c\/p\u003e \u003cp\u003eKey topics covered in the book include:\u003c\/p\u003e \u003cul\u003e\n\u003cli\u003eApplication of molecular dynamics simulations and related approaches in drug discovery\u003c\/li\u003e\n\u003cli\u003eThe application of QM, hybrid approaches such as QM\/MM, and fragment molecular orbital framework for understanding protein-ligand interactions\u003c\/li\u003e\n\u003cli\u003eAdoption of artificial intelligence in pre-clinical drug discovery, encompassing protein structure prediction, generative modeling for \u003ci\u003ede novo\u003c\/i\u003e design, and virtual screening.\u003c\/li\u003e\n\u003cli\u003eTechniques for navigating and visualizing the chemical space, along with harnessing big data to drive drug discovery efforts.\u003c\/li\u003e\n\u003cli\u003eMethods for performing ultra-large-scale virtual screening for hit identification.\u003c\/li\u003e\n\u003cli\u003eComputational strategies for designing new therapeutic models, including PROTACs and molecular glues.\u003c\/li\u003e\n\u003cli\u003eIn silico ADMET approaches for predicting a variety of pharmacokinetic and physicochemical endpoints.\u003c\/li\u003e\n\u003cli\u003eThe role of computing technologies like quantum computing and cloud computing in accelerating drug discovery\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eThis book will provide readers an overview of the latest advancements in \u003ci\u003eComputational Drug Discovery\u003c\/i\u003e and serve as a valuable resource for professionals engaged in drug discovery.\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eVolume 1\u003c\/p\u003e \u003cp\u003ePreface xv\u003c\/p\u003e \u003cp\u003eAcknowledgments xix\u003c\/p\u003e \u003cp\u003eAbout the Editors xxi\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I Molecular Dynamics and Related Methods in Drug Discovery 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Binding Free Energy Calculations in Drug Discovery 3\u003cbr\u003e\u003ci\u003eAnitade Ruiter and Chris Oostenbrink\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Gaussian Accelerated Molecular Dynamics in Drug Discovery 21\u003cbr\u003e\u003ci\u003eHung N. Do, Jinan Wang, Keya Joshi, Kushal Koirala, and Yinglong Miao\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 MD Simulations for Drug-Target(Un)binding Kinetics 45\u003cbr\u003e\u003ci\u003eSteffen Wolf\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Solvation Thermodynamics and its Applications in Drug Discovery 65\u003cbr\u003e\u003ci\u003eKuzhanthaivelan Saravanan and Ramesh K. Sistla\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Site-Identification by Ligand Competitive Saturation as a Paradigm of Co-solvent MD Methods 83\u003cbr\u003e\u003ci\u003eAsuka A. Orr and Alexander D. MacKerell Jr.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II Quantum Mechanics Application for Drug Discovery 119\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e6 QM\/MM for Structure-Based Drug Design: Techniques and Applications 121\u003cbr\u003e\u003ci\u003eMarc W. van der Kamp and Jaida Begum\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Recent Advances in Practical Quantum Mechanics and Mixed-QM\/MM-Driven X-Ray Crystallography and Cryogenic Electron Microscopy (Cryo-EM) and Their Impact on Structure-Based Drug Discovery 157\u003cbr\u003e\u003ci\u003eOleg Borbulevych and Lance M. Westerhoff\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Quantum-Chemical Analyses of Interactions for Biochemical Applications 183\u003cbr\u003e\u003ci\u003eDmitri G. Fedorov\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III Artificial Intelligence in Pre-clinical Drug Discovery 211\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9 The Role of Computer-Aided Drug Design in Drug Discovery 213\u003cbr\u003e\u003ci\u003eStormvander Voort, Andreas Bender, and Bart A. Westerman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 AI-Based Protein Structure Predictions and Their Implications in Drug Discovery 227\u003cbr\u003e\u003ci\u003eTahsin F. Kellici, Dimitar Hristozov, and Inaki Morao\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Deep Learning for the Structure-Based Binding Free Energy Prediction of Small Molecule Ligands 255\u003cbr\u003e\u003ci\u003eVenkatesh Mysore, Nilkanth Patel, and Adegoke Ojewole\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Using Artificial Intelligence for de novo Drug Design and Retrosynthesis 275\u003cbr\u003e\u003ci\u003eRohit Arora, Nicolas Brosse, Clarisse Descamps, Nicolas Devaux, Nicolas Do Huu, Philippe Gendreau, Yann Gaston-Mathé, Maud Parrot, Quentin Perron, and Hamza Tajmouati\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Reliability and Applicability Assessment for Machine Learning Models 299\u003cbr\u003e\u003ci\u003eFabio Urbina and Sean Ekins\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eVolume 2\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePreface xv\u003c\/p\u003e \u003cp\u003eAcknowledgments xix\u003c\/p\u003e \u003cp\u003eAbout the Editors xxi\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart IV Chemical Space and Knowledge-Based Drug Discovery 315\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e14 Enumerable Libraries and Accessible Chemical Space in Drug Discovery 317\u003cbr\u003e\u003ci\u003eTim Knehans, Nicholas A. Boyles, and Pieter H. Bos\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Navigating Chemical Space 337\u003cbr\u003e\u003ci\u003eAkos Tarcsay, András Volford, Jonathan Buttrick, Jan-Constantin Christopherson, Máte Erdos, and Zoltán B. Szabó\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Visualization, Exploration, and Screening of Chemical Space in Drug Discovery 365\u003cbr\u003e\u003ci\u003eJosé J. Naveja, Fernanda I. Saldívar-González, Diana L. Prado-Romero, Angel J.Ruiz-Moreno, Marco Velasco-Velázquez, Ramón Alain Miranda-Quintana, and José L. Medina-Franco\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 SAR Knowledge Bases for Driving Drug Discovery 395\u003cbr\u003e\u003ci\u003eNishanth Kandepedu, Anil Kumar Manchala, and Norman Azoulay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Cambridge Structural Database (CSD)–Drug Discovery Through Data Mining \u0026amp; Knowledge-Based Tools 419\u003cbr\u003e\u003ci\u003eFrancesca Stanzione, Rupesh Chikhale, and Laura Friggeri\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart V Structure-Based Virtual Screening Using Docking 441\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e19 Structure-Based Ultra-Large Virtual Screenings 443\u003cbr\u003e\u003ci\u003eChristoph Gorgulla\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Community Benchmarking Exercises for Docking and Scoring 471\u003cbr\u003e\u003ci\u003eBharti Devi, Anurag TK Baidya, and Rajnish Kumar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePartVI In Silico ADMET Modeling 495\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e21 Advances in the Application of In Silico ADMET Models–An Industry Perspective 497\u003cbr\u003e\u003ci\u003eWenyi Wang, Fjodor Melnikov, Joe Napoli, and Prashant Desai\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart VII Computational Approaches for New Therapeutic Modalities 537\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e22 Modeling the Structures of Ternary Complexes Mediated by Molecular Glues 539\u003cbr\u003e\u003ci\u003eMichael L. Drummond\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Free Energy Calculations in Covalent Drug Design 561\u003cbr\u003e\u003ci\u003eLevente M. Mihalovits, György G. Ferenczy, and György M. Keseru\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart VIII Computing Technologies Driving Drug Discovery 579\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e24 Orion A Cloud-Native Molecular Design Platform 581\u003cbr\u003e\u003ci\u003eJesper Sorensen, Caitlin C. Bannan, Gaetano Calabrò, Varsha Jain, Grigory Ovanesyan, Addison Smith, She Zhang, Christopher I. Bayly, Tom A. Darden, Matthew T. Geballe, David N. LeBard, Mark McGann, Joseph B. Moon, Hari S. Muddana, Andrew Shewmaker, Jharrod LaFon, Robert W. Tolbert, A. Geoffrey Skillman, and Anthony Nicholls\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Cloud-Native Rendering Platform and GPUs Aid Drug Discovery 617\u003cbr\u003e\u003ci\u003eMark Ross, Michael Drummond, Lance Westerhoff, Xavier Barbeu, Essam Metwally, Sasha Banks-Louie, Kevin Jorissen, Anup Ojah, and Ruzhu Chen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 The Quantum Computing Paradigm 627\u003cbr\u003e\u003ci\u003eThomas Ehmer, Gopal Karemore, and Hans Melo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 679\u003c\/p\u003e","brand":"Wiley-VCH Verlag GmbH","offers":[{"title":"Default Title","offer_id":48743126663511,"sku":"9783527351664","price":184.31,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9783527351664.jpg?v=1720064227"},{"product_id":"coberts-manual-of-drug-safety-and-pharmacovigilance-third-edition-9789811215230","title":"Cobert's Manual Of Drug Safety And","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eCompletely revised and updated, Cobert's Manual of Drug Safety and Pharmacovigilance, Third Edition, is a how-to manual for those working in the fields of drug safety, clinical research, pharmacology, regulatory affairs, risk management, quality\/compliance, and in government and legal professions.This comprehensive and practical guide discusses the theory and the practicalities of drug safety (also known as pharmacovigilance), and provides essential information on drug safety and regulations in the United States, Europe Union, and more, including: recognizing, monitoring, reporting, and cataloging serious adverse drug reactions.Cobert's Manual of Drug Safety and Pharmacovigilance, Third Edition, teaches the daily practice of drug safety in industry, hospitals, the FDA and other health agencies — both in the United States and around the world — and provides critical information about what to do when confronted with a drug safety problem.Related Link(s)","brand":"World Scientific Publishing Co Pte Ltd","offers":[{"title":"Default Title","offer_id":48743276675415,"sku":"9789811215230","price":52.25,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9789811215230.jpg?v=1720064884"},{"product_id":"how-medicines-work-illustrated-9789811248191","title":"How Medicines Work: Illustrated","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis highly illustrated volume will describe, through clear diagrams and concise text, how the most prescribed, as well as new medicines, work in the body for a broad range of diseases. By bringing this knowledge together in one place, we will seek to answer the question, 'What is the impact of the accelerating knowledge in biology, drug research and medical sciences on the development and approval of medicines for the treatment of a wide range of diseases'. Furthermore, information on how a successful drug works can make the case for a particular therapy and provide an informed dialog between a patient and physician, or a professor and a student, or a regulator and pharmaceutical scientist.With the continuing explosion of medical information, the book addresses the following themes:This book breaks important new ground by focusing on the cellular biochemistry of selected diseases and how the respective drug works, using a concise, focused and non-technical graphic review.","brand":"World Scientific Publishing Co Pte Ltd","offers":[{"title":"Default Title","offer_id":48743282737495,"sku":"9789811248191","price":999.99,"currency_code":"GBP","in_stock":false}]},{"product_id":"clinical-physiology-of-acidbase-and-electrolyte-disorders-9780071346825","title":"Clinical Physiology of AcidBase and Electrolyte","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eâœThe core of information that the clinician should possessâ -- From the Preface\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eDoody's Core Titles for 2021!\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eLike its highly acclaimed predecessors, the Fifth Edition of this classic effectively integrates the essentials of renal and electrolyte physiology with the common clinical disorders of acid-base and electrolyte balance.\u003c\/p\u003e\u003cp\u003eFEATURES:\u003cbr\u003e*An easy-to-read writing style that demystifies this difficult subject\u003cbr\u003e*Basic science coverage of water and electrolyte physiology, renal physiology, and regulation of water and electrolyte balance\u003cbr\u003e*Clinical chapters that quickly guide you through key points of etiology, pathophysiology, symptoms, diagnosis, and treatment of common disorders\u003cbr\u003e*Crystal clear figures and handy tables that summarize key information\u003cbr\u003e*End-of-chapter problems that test mastery of the material\u003c\/p\u003e\u003cp\u003eNEW IN THIS EDITION:\u003cbr\u003e*New sections on endothelin and nitric oxide\u003cbr\u003e*State-of-the-art information on the properties of the c\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePart One: Renal Physiology. Chapter 1: Introduction to Renal Function. Chapter 2: Renal Circulation and Glomerular Filtration Rate.  Chapter 3: Proximal Tubule. Chapter 4: Loop of Henle and the Countercurrent Mechanism. Chapter 5: Functions of the Distal Nephron. Chapter 6: Effects of Hormones on Renal Function. Part Two: Regulation of Water and Electrolyte Balance. Chapter 7: The Total Body Water and the Plasma Sodium Concentration. Chapter 8: Regulation of the Effective Circulating Volume. Chapter 9: Regulation of Plasma Osmolality.  Chapter 10: Acid-Base Physiology. Chapter 11: Regulation of Acid-Base Balance. Chapter 12: Potassium Homeostasis. Part Three: Physiologic Approach to Acid-Base and Electrolyte Disorders. Chapter 13: Meaning and Application of Urine Chemistries. Chapter 14: Hypovolemic States. Chapter 15: Clinical Use of Diuretics. Chapter 16: Edematous States. Chapter 17: Introduction to Simple and Mixed Acid-Base Disorders. Chapter 18: Metabolic Alkalosis. Chapter 19: Metabolic Acidosis. Chapter 20: Respiratory Acidosis. Chapter 21: Respiratory Alkalosis. Chapter 22: Introduction to Disorders of Osmolality. Chapter 23: Hypoosmolal States - Hyponatremia. Chapter 24: Hyperosmolal States - Hyponatremia. Chapter 25: Hyperosmolal States - Hyperglycemia Chapter 26: Introduction to Disorders of Potassium Balance. Chapter 27: Hypokalemia. Chapter 28: Hyperkalemia. Chapter 29: Answers to the Problems. Chapter 30: Summary of Equations and Formulas.\u003c\/p\u003e","brand":"McGraw-Hill Education - Europe","offers":[{"title":"Default Title","offer_id":48864146063703,"sku":"9780071346825","price":77.39,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780071346825.jpg?v=1722270600"},{"product_id":"pharmacology-flash-cards-9780323355643","title":"Pharmacology Flash Cards","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePharmacology Flash Cards Fourth Edition    Section I: Autonomic, Autacoid, and Neuromuscular Drugs  Section II: Cardiovascular Drugs  Section III: Lipid, Coagulation, and Hematopoiesis Drugs  Section IV: Central Nervous System Depressant Drugs  Section V: Psychotherapeutic Drugs  Section VI: Analgesic and Antimigraine Drugs  Section VII: Neurodegenerative Disease Drugs and Antidotes  Section VIII: Anesthetic Drugs  Section IX: Gastrointestinal Drugs  Section X: Respiratory Drugs and Antihistamines  Section XI: Musculoskeletal Drugs  Section XII: Endocrine Drugs Section XIII: Antibacterial Drugs  Section XIV: Antifungal, Antiviral, and Antiparasitic Drugs  Section XV: Antineoplastic And Immunosuppressant Drugs","brand":"Elsevier - Health Sciences Division","offers":[{"title":"Default Title","offer_id":48864423084375,"sku":"9780323355643","price":35.14,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780323355643.jpg?v=1722271872"},{"product_id":"ciottones-disaster-medicine-9780323809320","title":"Ciottones Disaster Medicine","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePart 1: Overview of Disaster Management       Section 1: Introduction   Section 2: Domestic and International Resources   Section 3: Pre-Event Topics   Section 4: Event-Response Topics   Section 5: Mechanical Operations in Disasters   Section 6: Post-Event Topics   Section 7: Topics Unique to Terrorist Events and High-Threat Disaster Response   Section 8: Operational Medicine    Part 2: Management of Specific Event Types       Section 9: Natural Disasters   Section 10: Nuclear\/Radiation Events   Section 11: Chemical Events   Section 12: Biological Events: Introduction   Section 12: Biological Events, Part 1: Bacterial Agents   Section 12: Biological Events, Part 2: Viral Agents   Section 12: Biological Agents, Part 3, Toxins   Section 12: Biological Agents, Part 4: Other Biological Agents   Section 13: Events Resulting in Blast Injuries   Section 14: Events Resulting in Burn Injuries   Section 15: Events Resulting in Ballistic Injuries   Section 16: Events Resulting in Structural Collapse\/Crashing\/Crushing   Section 17: Other Events\/Combination Events","brand":"Elsevier - Health Sciences Division","offers":[{"title":"Default Title","offer_id":48864429867351,"sku":"9780323809320","price":116.09,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780323809320.jpg?v=1722271904"},{"product_id":"rang-dales-pharmacology-9780323873956","title":"Rang  Dales Pharmacology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eSECTION 1 GENERAL PRINCIPLES 1. What is pharmacology? 2. How drugs act: general principles 3. How drugs act: molecular aspects 4. How drugs act: cellular aspects - excitation, contraction and secretion 5. How drugs act: Biopharmaceuticals and gene therapy 6. Cell proliferation, apoptosis, repair and regeneration 7. Cellular mechanisms: host defence 8. Method and measurement in pharmacology 9. Absorption and distribution of drugs 10. Drug metabolism and elimination 11. Pharmacokinetics 12. Individual variation, pharmacogenomics and personalised medicine SECTION 2 CHEMICAL MEDIATORS 13. Chemical mediators and the autonomic nervous system 14. Cholinergic transmission 15. Noradrenergic transmission 16. 5-Hydroxytryptamine and purines 17. Local hormones: histamine, lipids, peptides and proteins   18. Cannabinoids 19. Nitric oxide and related mediators SECTION 3 DRUGS AFFECTING MAJOR ORGAN SYSTEMS 20. The heart 21. The vascular system 22. Atherosclerosis and lipoprotein metabolism 23. Haemostasis and thrombosis 24. Haemopoietic system and treatment of anaemia 25. Anti-inflammatory and immunosuppressant drugs 26. Skin 27. Eye 28. Respiratory system 29. The kidney and urinary system 30. The gastrointestinal tract 31. The control of blood glucose and drug treatment of diabetes mellitus 32. Obesity 33. The pituitary and the adrenal cortex 34. Thyroid 35. The reproductive system 36. Bone metabolism SECTION 4 NERVOUS SYSTEM 37. Chemical transmission and drug action in the central nervous system 38. Amino acid transmitters 39. Other transmitters and modulators 40. Neurodegenerative diseases 41. General anaesthetic agents 42. Headache 43. Analgesic drugs 44. Local anaesthetics and other drugs affecting sodium channels 45. Anxiolytic and hypnotic drugs 46. Antiepileptic drugs 47. Antipsychotic drugs 48. Antidepressant drugs 49. Psychoactive drugs 50. Drug use and addiction SECTION 5 DRUGS USED FOR THE TREATMENT OF INFECTIONS AND CANCER 51. Basic principles of antimicrobial chemotherapy 52. Antibacterial drugs 53. Antiviral drugs 54. Antifungal drugs 55. Antiprotozoal drugs 56. Antihelminthic drugs 57. Anticancer drugs SECTION 6 SPECIAL TOPICS 58. Harmful effects of drugs 59. Lifestyle drugs and drugs in sport 60. Drug discovery and development Index","brand":"Elsevier - Health Sciences Division","offers":[{"title":"Default Title","offer_id":48864431767895,"sku":"9780323873956","price":54.14,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780323873956.jpg?v=1722271913"},{"product_id":"raus-respiratory-care-pharmacology-9780323871556","title":"Raus Respiratory Care Pharmacology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eUnit A: Basic Concepts and Principles in Pharmacology 1 Introduction to Respiratory Care Pharmacology 2 Principles of Drug Action 3 Administration of Aerosolized Agents 4 Calculating Drug Doses 5 Central and Peripheral Nervous Systems Unit B: Drugs Used to Treat the Respiratory System 6 Adrenergic (Sympathomimetic) Bronchodilators 7 Anticholinergic (Parasympatholytic) Bronchodilators 8 Xanthines 9 Mucus-Controlling Drug Therapy 10 Surfactant Agents 11 Corticosteroids in Respiratory Care 12 Nonsteroidal Antiasthma Agents 13 Aerosolized Antiinfective Agents 14 Antimicrobial Agents 15 Cold and Cough Agents 16 Selected Agents of Pulmonary Value 17 Neonatal and Pediatric Aerosolized Drug Therapy Unit C: Critical Care, Cardiovascular, and Polysomnography Agents 18 Skeletal Muscle Relaxants (Neuromuscular Blocking Agents) 19 Diuretic Agents 20 Drugs Affecting the Central Nervous System 21 Vasopressors, Inotropes, and Antiarrhythmic Agents 22 Drugs Affecting Circulation: Antihypertensives, Antianginals, Antithrombotics 23 Sleep and Sleep Pharmacology Appendixes A Answers to Self-Assessment Questions and Clinical Scenarios B Units and Systems of Measurement C Acceptable Mixtures of Most Commonly Prescribed Respiratory Care Drugs Glossary of Selected Terms Index Abbreviations, Inside back cover","brand":"Elsevier - Health Sciences Division","offers":[{"title":"Default Title","offer_id":48864431833431,"sku":"9780323871556","price":86.44,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780323871556.jpg?v=1722271914"},{"product_id":"the-truth-about-the-drug-companies-9780375760945","title":"The Truth About the Drug Companies","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eDuring her two decades at \u003ci\u003eThe\u003c\/i\u003e \u003ci\u003eNew England Journal of Medicine\u003c\/i\u003e, Dr. Marcia Angell had a front-row seat on the appalling spectacle of the pharmaceutical industry. She watched drug companies stray from their original mission of discovering and manufacturing useful drugs and instead become vast marketing machines with unprecedented control over their own fortunes. She saw them gain nearly limitless influence over medical research, education, and how doctors do their jobs. She sympathized as the American public, particularly the elderly, struggled and increasingly failed to meet spiraling prescription drug prices. Now, in this bold, hard-hitting new book, Dr. Angell exposes the shocking truth of what the pharmaceutical industry has become-and argues for essential, long-overdue change.\u003cbr\u003e\u003cbr\u003eCurrently Americans spend a staggering $200 billion each year on prescription drugs. As Dr. Angell powerfully demonstrates, claims that high drug prices are necessary to fund research and","brand":"Random House Publishing Group","offers":[{"title":"Default Title","offer_id":48864531349847,"sku":"9780375760945","price":14.24,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780375760945.jpg?v=1722272349"},{"product_id":"molecular-pharmacology-9780470684436","title":"Molecular Pharmacology","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eProvides an introduction to the rapidly expanding field of molecular pharmacology. Adopting a drug target-based, rather than the traditional organ\/system based approach, this book reflects the advances and research trend towards molecular based drug design, derived from a detailed understanding of chemical responses in the body.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e“Overall, it could be the basis of an excellent course for junior pharmacologists in basic science research who need a greater focus on the mechanisms of drug action rather than an encyclopedic survey of clinical drug use.”  (\u003ci\u003eDoody’s\u003c\/i\u003e, 26 July 2013)\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePreface ix  \u003cp\u003eAbbreviations x\u003c\/p\u003e \u003cp\u003e1 Introduction to Drug Targets and Molecular Pharmacology 1\u003c\/p\u003e \u003cp\u003e1.1 Introduction to molecular pharmacology 1\u003c\/p\u003e \u003cp\u003e1.2 Scope of this textbook 2\u003c\/p\u003e \u003cp\u003e1.3 The nature of drug targets 3\u003c\/p\u003e \u003cp\u003e1.4 Future drug targets 7\u003c\/p\u003e \u003cp\u003e1.5 Molecular pharmacology and drug discovery 11\u003c\/p\u003e \u003cp\u003eReferences 12\u003c\/p\u003e \u003cp\u003e2 Molecular Cloning of Drug Targets 13\u003c\/p\u003e \u003cp\u003e2.1 Introduction to molecular cloning – from DNA to drug discovery 13\u003c\/p\u003e \u003cp\u003e2.2 ‘Traditional’ pharmacology 14\u003c\/p\u003e \u003cp\u003e2.3 The relevance of recombinant DNA technology to pharmacology\/drug\u003c\/p\u003e \u003cp\u003ediscovery 14\u003c\/p\u003e \u003cp\u003e2.4 The ‘cloning’ of drug targets 15\u003c\/p\u003e \u003cp\u003e2.5 What information can DNA cloning provide? 20\u003c\/p\u003e \u003cp\u003e2.6 Comparing the pharmacologic profile of the ‘cloned’ and the ‘native’\u003c\/p\u003e \u003cp\u003edrug target 23\u003c\/p\u003e \u003cp\u003e2.7 Reverse pharmacology illustrated on orphan GPCRs 24\u003c\/p\u003e \u003cp\u003e2.8 Summary 27\u003c\/p\u003e \u003cp\u003eReferences 27\u003c\/p\u003e \u003cp\u003e3 G Protein-coupled Receptors 31\u003c\/p\u003e \u003cp\u003e3.1 Introduction to G protein-coupled receptors 31\u003c\/p\u003e \u003cp\u003e3.2 Heterotrimeric G-proteins 36\u003c\/p\u003e \u003cp\u003e3.3 Signal transduction pathways 40\u003c\/p\u003e \u003cp\u003e3.4 Desensitisation and down-regulation of GPCR signalling 44\u003c\/p\u003e \u003cp\u003e3.5 Constitutive GPCR activity 45\u003c\/p\u003e \u003cp\u003e3.6 Promiscuous G-protein coupling 47\u003c\/p\u003e \u003cp\u003e3.7 Agonist-directed signalling 48\u003c\/p\u003e \u003cp\u003e3.8 Allosteric modulators of GPCR function 49\u003c\/p\u003e \u003cp\u003e3.9 Pharmacological chaperones for GPCRs 50\u003c\/p\u003e \u003cp\u003e3.10 GPCR dimerisation 51\u003c\/p\u003e \u003cp\u003e3.11 GPCR splice variants 63\u003c\/p\u003e \u003cp\u003e3.12 Summary 67\u003c\/p\u003e \u003cp\u003eReferences 67\u003c\/p\u003e \u003cp\u003eUseful Web sites 70\u003c\/p\u003e \u003cp\u003e4 Ion Channels 71\u003c\/p\u003e \u003cp\u003e4.1 Introduction 71\u003c\/p\u003e \u003cp\u003e4.2 Voltage-gated ion channels 73\u003c\/p\u003e \u003cp\u003e4.3 Other types of voltage-gated ion channels 89\u003c\/p\u003e \u003cp\u003e4.4 Ligand-gated ion channels 109\u003c\/p\u003e \u003cp\u003e4.5 Summary 125\u003c\/p\u003e \u003cp\u003eReferences 125\u003c\/p\u003e \u003cp\u003e5 Transporter Proteins 129\u003c\/p\u003e \u003cp\u003e5.1 Introduction 129\u003c\/p\u003e \u003cp\u003e5.2 Classification 129\u003c\/p\u003e \u003cp\u003e5.3 Structural analysis of transporters 132\u003c\/p\u003e \u003cp\u003e5.4 Transporter families of pharmacological interest 133\u003c\/p\u003e \u003cp\u003e5.5 Transporters and cellular homeostasis 167\u003c\/p\u003e \u003cp\u003e5.6 Summary 169\u003c\/p\u003e \u003cp\u003eReferences 169\u003c\/p\u003e \u003cp\u003e6 Cystic Fibrosis: Alternative Approaches to the Treatment of a Genetic Disease 175\u003c\/p\u003e \u003cp\u003e6.1 Introduction 175\u003c\/p\u003e \u003cp\u003e6.2 Cystic fibrosis transmembrane conductance regulator 179\u003c\/p\u003e \u003cp\u003e6.3 Mutations in CFTR 183\u003c\/p\u003e \u003cp\u003e6.4 Why is cystic fibrosis so common? 184\u003c\/p\u003e \u003cp\u003e6.5 Animal models of Cystic fibrosis 186\u003c\/p\u003e \u003cp\u003e6.6 Pharmacotherapy 186\u003c\/p\u003e \u003cp\u003e6.7 Gene therapy 191\u003c\/p\u003e \u003cp\u003e6.8 Conclusion 195\u003c\/p\u003e \u003cp\u003eReferences 196\u003c\/p\u003e \u003cp\u003e7 Pharmacogenomics 201\u003c\/p\u003e \u003cp\u003e7.1 Types of genetic variation in the human genome 201\u003c\/p\u003e \u003cp\u003e7.2 Thiopurine S-methyltransferase and K+ channel polymorphisms 202\u003c\/p\u003e \u003cp\u003e7.3 Polymorphisms affecting drug metabolism 204\u003c\/p\u003e \u003cp\u003e7.4 Methods for detecting genetic polymorphisms 209\u003c\/p\u003e \u003cp\u003e7.5 Genetic variation in drug transporters 211\u003c\/p\u003e \u003cp\u003e7.6 Genetic variation in G protein coupled receptors 215\u003c\/p\u003e \u003cp\u003e7.7 Summary 225\u003c\/p\u003e \u003cp\u003eReferences 225\u003c\/p\u003e \u003cp\u003eUseful Web sites 226\u003c\/p\u003e \u003cp\u003e8 Transcription Factors and Gene Expression 227\u003c\/p\u003e \u003cp\u003e8.1 Control of gene expression 227\u003c\/p\u003e \u003cp\u003e8.2 Transcription factors 229\u003c\/p\u003e \u003cp\u003e8.3 CREB 233\u003c\/p\u003e \u003cp\u003e8.4 Nuclear receptors 238\u003c\/p\u003e \u003cp\u003e8.5 Peroxisome proliferator-activated receptors 240\u003c\/p\u003e \u003cp\u003e8.6 Growth factors 247\u003c\/p\u003e \u003cp\u003e8.7 Alternative splicing 247\u003c\/p\u003e \u003cp\u003e8.8 RNA editing 251\u003c\/p\u003e \u003cp\u003e8.9 The importance of non-coding RNAs in gene expression 257\u003c\/p\u003e \u003cp\u003e8.10 Summary 270\u003c\/p\u003e \u003cp\u003eReferences 271\u003c\/p\u003e \u003cp\u003e9 Cellular Calcium 277\u003c\/p\u003e \u003cp\u003e9.1 Introduction 277\u003c\/p\u003e \u003cp\u003e9.2 Measurement of calcium 278\u003c\/p\u003e \u003cp\u003e9.3 The exocrine pancreas 289\u003c\/p\u003e \u003cp\u003e9.4 Calcium signalling in pancreatic acinar cells 292\u003c\/p\u003e \u003cp\u003e9.5 Nuclear calcium signalling 303\u003c\/p\u003e \u003cp\u003e9.6 Conclusions 310\u003c\/p\u003e \u003cp\u003eReferences 311\u003c\/p\u003e \u003cp\u003e10 Genetic Engineering of Mice 315\u003c\/p\u003e \u003cp\u003e10.1 Introduction to genetic engineering 315\u003c\/p\u003e \u003cp\u003e10.2 Genomics and the accumulation of sequence data 315\u003c\/p\u003e \u003cp\u003e10.3 The mouse as a model organism 318\u003c\/p\u003e \u003cp\u003e10.4 Techniques for genetic engineering 319\u003c\/p\u003e \u003cp\u003e10.5 Examples of genetically-engineered mice 332\u003c\/p\u003e \u003cp\u003e10.6 Summary 334\u003c\/p\u003e \u003cp\u003eReferences 334\u003c\/p\u003e \u003cp\u003e11 Signalling Complexes: Protein-protein Interactions and Lipid Rafts 339\u003c\/p\u003e \u003cp\u003e11.1 Introduction to cell signalling complexes 339\u003c\/p\u003e \u003cp\u003e11.2 Introduction to GPCR interacting proteins 340\u003c\/p\u003e \u003cp\u003e11.3 Methods used to identify GPCR interacting proteins 340\u003c\/p\u003e \u003cp\u003e11.4 Functional roles of GPCR interacting proteins 345\u003c\/p\u003e \u003cp\u003e11.5 GPCR signalling complexes 348\u003c\/p\u003e \u003cp\u003e11.6 GPCR and ion channel complexes 355\u003c\/p\u003e \u003cp\u003e11.7 Ion channel signalling complexes 356\u003c\/p\u003e \u003cp\u003e11.8 Development of pharmaceuticals that target GPCR interacting proteins 356\u003c\/p\u003e \u003cp\u003e11.9 Development of pharmaceuticals that target protein-protein interactions 356\u003c\/p\u003e \u003cp\u003e11.10 Lipid rafts 357\u003c\/p\u003e \u003cp\u003e11.11 Receptor-mediated endocytosis 361\u003c\/p\u003e \u003cp\u003e11.12 Summary 364\u003c\/p\u003e \u003cp\u003eReferences 364\u003c\/p\u003e \u003cp\u003e12 Recombinant Proteins and Immunotherapeutics 367\u003c\/p\u003e \u003cp\u003e12.1 Introduction to immunotherapeutics 367\u003c\/p\u003e \u003cp\u003e12.2 Historical background of immunotherapeutics 368\u003c\/p\u003e \u003cp\u003e12.3 Basis of immunotherapeutics 368\u003c\/p\u003e \u003cp\u003e12.4 Types of immunotherapeutics 369\u003c\/p\u003e \u003cp\u003e12.5 Humanisation of antibody therapy 372\u003c\/p\u003e \u003cp\u003e12.6 Immunotherapeutics in clinical practice 376\u003c\/p\u003e \u003cp\u003e12.7 Advantages and disadvantages of immunotherapy 378\u003c\/p\u003e \u003cp\u003e12.8 The future 379\u003c\/p\u003e \u003cp\u003e12.9 Summary 380\u003c\/p\u003e \u003cp\u003eReferences 380\u003c\/p\u003e \u003cp\u003eGlossary 381\u003c\/p\u003e \u003cp\u003eIndex 403\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":48864637354327,"sku":"9780470684436","price":53.15,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470684436.jpg?v=1722272840"},{"product_id":"medicinal-natural-products-9780470741672","title":"Medicinal Natural Products","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eMedicinal Natural Products: A Biosynthetic Approach, Third Edition, provides a comprehensive and balanced introduction to natural products from a biosynthetic perspective, focussing on the metabolic sequences leading to various classes of natural products.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\"Students should be empowered for a deductive analysis of the presented substances.\" (\u003ci\u003eArzneimittelforschung\u003c\/i\u003e, December 2009)  \u003cp\u003e \"This new edition is an excellent text that is unrivaled in both its scope and overall coverage of natural products biosynthesis.\" (\u003ci\u003eJournal of Medicinal Chemistry\u003c\/i\u003e, August 2009)\u003c\/p\u003e  \u003cp\u003e \"There is no question that this is the best book available on the biosynthesis and bio-organic chemistry of medicinally important natural products.\" (\u003ci\u003eEducation in Chemistry\u003c\/i\u003e, September 2009)\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003e1 About this book, and how to use it \u003c\/b\u003e\u003cb\u003e1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThe subject 1\u003c\/p\u003e \u003cp\u003eThe aim 1\u003c\/p\u003e \u003cp\u003eThe approach 2\u003c\/p\u003e \u003cp\u003eThe topics 2\u003c\/p\u003e \u003cp\u003eThe figures 2\u003c\/p\u003e \u003cp\u003eFurther reading 3\u003c\/p\u003e \u003cp\u003eWhat to study 3\u003c\/p\u003e \u003cp\u003eWhat to learn 3\u003c\/p\u003e \u003cp\u003eNomenclature 3\u003c\/p\u003e \u003cp\u003eConventions regarding acids, bases, and ions 4\u003c\/p\u003e \u003cp\u003eSome common abbreviations 4\u003c\/p\u003e \u003cp\u003eFurther reading 5\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Secondary metabolism: the building blocks and construction mechanisms \u003c\/b\u003e\u003cb\u003e7\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePrimary and secondary metabolism 7\u003c\/p\u003e \u003cp\u003eThe building blocks 8\u003c\/p\u003e \u003cp\u003eThe construction mechanisms 11\u003c\/p\u003e \u003cp\u003eAlkylation reactions: nucleophilic substitution 12\u003c\/p\u003e \u003cp\u003eAlkylation reactions: electrophilic addition 12\u003c\/p\u003e \u003cp\u003eWagner–Meerwein rearrangements 15\u003c\/p\u003e \u003cp\u003eAldol and Claisen reactions 15\u003c\/p\u003e \u003cp\u003eImine formation and the Mannich reaction 18\u003c\/p\u003e \u003cp\u003eAmino acids and transamination 20\u003c\/p\u003e \u003cp\u003eDecarboxylation reactions 22\u003c\/p\u003e \u003cp\u003eOxidation and reduction reactions 24\u003c\/p\u003e \u003cp\u003eDehydrogenases 24\u003c\/p\u003e \u003cp\u003eOxidases 26\u003c\/p\u003e \u003cp\u003eMonooxygenases 26\u003c\/p\u003e \u003cp\u003eDioxygenases 26\u003c\/p\u003e \u003cp\u003eAmine oxidases 27\u003c\/p\u003e \u003cp\u003eBaeyer–Villiger monooxygenases 27\u003c\/p\u003e \u003cp\u003ePhenolic oxidative coupling 28\u003c\/p\u003e \u003cp\u003eHalogenation reactions 28\u003c\/p\u003e \u003cp\u003eGlycosylation reactions 31\u003c\/p\u003e \u003cp\u003eElucidating biosynthetic pathways 34\u003c\/p\u003e \u003cp\u003eFurther reading 38\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 The acetate pathway: fatty acids and polyketides \u003c\/b\u003e\u003cb\u003e39\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eFatty acid synthase: saturated fatty acids 39\u003c\/p\u003e \u003cp\u003eUnsaturated fatty acids 44\u003c\/p\u003e \u003cp\u003eUncommon fatty acids 53\u003c\/p\u003e \u003cp\u003eProstaglandins 58\u003c\/p\u003e \u003cp\u003eThromboxanes 64\u003c\/p\u003e \u003cp\u003eLeukotrienes 64\u003c\/p\u003e \u003cp\u003ePolyketide synthases: generalities 66\u003c\/p\u003e \u003cp\u003ePolyketide synthases: macrolides 68\u003c\/p\u003e \u003cp\u003ePolyketide synthases: linear polyketides and polyethers 90\u003c\/p\u003e \u003cp\u003eDiels–Alder cyclizations 96\u003c\/p\u003e \u003cp\u003ePolyketide synthases: aromatics 96\u003c\/p\u003e \u003cp\u003eCyclizations 99\u003c\/p\u003e \u003cp\u003ePost-polyketide synthase modifications 103\u003c\/p\u003e \u003cp\u003eStarter groups 116\u003c\/p\u003e \u003cp\u003eFurther reading 131\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 The shikimate pathway: aromatic amino acids and phenylpropanoids \u003c\/b\u003e\u003cb\u003e137\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAromatic amino acids and simple benzoic acids 137\u003c\/p\u003e \u003cp\u003ePhenylpropanoids 148\u003c\/p\u003e \u003cp\u003eCinnamic acids and esters 148\u003c\/p\u003e \u003cp\u003eLignans and lignin 152\u003c\/p\u003e \u003cp\u003ePhenylpropenes 156\u003c\/p\u003e \u003cp\u003eBenzoic acids from C\u003csub\u003e6\u003c\/sub\u003eC\u003csub\u003e3\u003c\/sub\u003e compounds 157\u003c\/p\u003e \u003cp\u003eCoumarins 161\u003c\/p\u003e \u003cp\u003eAromatic polyketides 166\u003c\/p\u003e \u003cp\u003eStyrylpyrones, diarylheptanoids 166\u003c\/p\u003e \u003cp\u003eFlavonoids and stilbenes 167\u003c\/p\u003e \u003cp\u003eFlavonolignans 173\u003c\/p\u003e \u003cp\u003eIsoflavonoids 174\u003c\/p\u003e \u003cp\u003eTerpenoid quinones 178\u003c\/p\u003e \u003cp\u003eFurther reading 184\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 The mevalonate and methylerythritol phosphate pathways: terpenoids and steroids \u003c\/b\u003e\u003cb\u003e187\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eMevalonic acid and methylerythritol phosphate 188\u003c\/p\u003e \u003cp\u003eHemiterpenes (C\u003csub\u003e5\u003c\/sub\u003e) 192\u003c\/p\u003e \u003cp\u003eMonoterpenes (C\u003csub\u003e10\u003c\/sub\u003e) 193\u003c\/p\u003e \u003cp\u003eIrregular monoterpenes 204\u003c\/p\u003e \u003cp\u003eIridoids (C\u003csub\u003e10\u003c\/sub\u003e) 206\u003c\/p\u003e \u003cp\u003eSesquiterpenes (C\u003csub\u003e15\u003c\/sub\u003e) 210\u003c\/p\u003e \u003cp\u003eDiterpenes (C\u003csub\u003e20\u003c\/sub\u003e) 223\u003c\/p\u003e \u003cp\u003eSesterterpenes (C\u003csub\u003e25\u003c\/sub\u003e) 234\u003c\/p\u003e \u003cp\u003eTriterpenes (C\u003csub\u003e30\u003c\/sub\u003e) 234\u003c\/p\u003e \u003cp\u003eTriterpenoid saponins 242\u003c\/p\u003e \u003cp\u003eSteroids 247\u003c\/p\u003e \u003cp\u003eStereochemistry and nomenclature 247\u003c\/p\u003e \u003cp\u003eCholesterol 248\u003c\/p\u003e \u003cp\u003ePhytosterols 251\u003c\/p\u003e \u003cp\u003eVitamin D 256\u003c\/p\u003e \u003cp\u003eSteroidal saponins 259\u003c\/p\u003e \u003cp\u003eCardioactive glycosides 265\u003c\/p\u003e \u003cp\u003eBile acids 275\u003c\/p\u003e \u003cp\u003eAdrenocortical hormones\/corticosteroids 277\u003c\/p\u003e \u003cp\u003eSemi-synthesis of corticosteroids 277\u003c\/p\u003e \u003cp\u003eProgestogens 287\u003c\/p\u003e \u003cp\u003eOestrogens 290\u003c\/p\u003e \u003cp\u003eAndrogens 296\u003c\/p\u003e \u003cp\u003eTetraterpenes (C\u003csub\u003e40\u003c\/sub\u003e) 298\u003c\/p\u003e \u003cp\u003eHigher terpenoids 306\u003c\/p\u003e \u003cp\u003eFurther reading 306\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Alkaloids \u003c\/b\u003e\u003cb\u003e311\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAlkaloids derived from ornithine 311\u003c\/p\u003e \u003cp\u003ePolyamines 311\u003c\/p\u003e \u003cp\u003ePyrrolidine and tropane alkaloids 312\u003c\/p\u003e \u003cp\u003ePyrrolizidine alkaloids 324\u003c\/p\u003e \u003cp\u003eAlkaloids derived from lysine 326\u003c\/p\u003e \u003cp\u003ePiperidine alkaloids 326\u003c\/p\u003e \u003cp\u003eQuinolizidine alkaloids 328\u003c\/p\u003e \u003cp\u003eIndolizidine alkaloids 330\u003c\/p\u003e \u003cp\u003eAlkaloids derived from nicotinic acid 331\u003c\/p\u003e \u003cp\u003ePyridine alkaloids 331\u003c\/p\u003e \u003cp\u003eAlkaloids derived from tyrosine 336\u003c\/p\u003e \u003cp\u003ePhenylethylamines and simple tetrahydroisoquinoline alkaloids 336\u003c\/p\u003e \u003cp\u003eModified benzyltetrahydroisoquinoline alkaloids 346\u003c\/p\u003e \u003cp\u003ePhenethylisoquinoline alkaloids 359\u003c\/p\u003e \u003cp\u003eTerpenoid tetrahydroisoquinoline alkaloids 363\u003c\/p\u003e \u003cp\u003eAmaryllidaceae alkaloids 365\u003c\/p\u003e \u003cp\u003eAlkaloids derived from tryptophan 366\u003c\/p\u003e \u003cp\u003eSimple indole alkaloids 366\u003c\/p\u003e \u003cp\u003eSimple β-carboline alkaloids 369\u003c\/p\u003e \u003cp\u003eTerpenoid indole alkaloids 369\u003c\/p\u003e \u003cp\u003eQuinoline alkaloids 380\u003c\/p\u003e \u003cp\u003ePyrroloindole alkaloids 385\u003c\/p\u003e \u003cp\u003eErgot alkaloids 387\u003c\/p\u003e \u003cp\u003eAlkaloids derived from anthranilic acid 395\u003c\/p\u003e \u003cp\u003eQuinazoline alkaloids 395\u003c\/p\u003e \u003cp\u003eQuinoline and acridine alkaloids 396\u003c\/p\u003e \u003cp\u003eAlkaloids derived from histidine 398\u003c\/p\u003e \u003cp\u003eImidazole alkaloids 398\u003c\/p\u003e \u003cp\u003eAlkaloids derived by amination reactions 400\u003c\/p\u003e \u003cp\u003eAcetate-derived alkaloids 401\u003c\/p\u003e \u003cp\u003ePhenylalanine-derived alkaloids 401\u003c\/p\u003e \u003cp\u003eTerpenoid alkaloids 406\u003c\/p\u003e \u003cp\u003eSteroidal alkaloids 406\u003c\/p\u003e \u003cp\u003ePurine alkaloids 413\u003c\/p\u003e \u003cp\u003eCaffeine 413\u003c\/p\u003e \u003cp\u003eSaxitoxin and tetrodotoxin 416\u003c\/p\u003e \u003cp\u003eFurther reading 417\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Peptides, proteins, and other amino acid derivatives \u003c\/b\u003e\u003cb\u003e421\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003ePeptides and proteins 421\u003c\/p\u003e \u003cp\u003eRibosomal peptide biosynthesis 422\u003c\/p\u003e \u003cp\u003ePeptide hormones 426\u003c\/p\u003e \u003cp\u003eThyroid hormones 426\u003c\/p\u003e \u003cp\u003eHypothalamic hormones 427\u003c\/p\u003e \u003cp\u003eAnterior pituitary hormones 429\u003c\/p\u003e \u003cp\u003ePosterior pituitary hormones 430\u003c\/p\u003e \u003cp\u003ePancreatic hormones 432\u003c\/p\u003e \u003cp\u003eInterferons 433\u003c\/p\u003e \u003cp\u003eOpioid peptides 434\u003c\/p\u003e \u003cp\u003eRibosomal peptide toxins 434\u003c\/p\u003e \u003cp\u003eEnzymes 438\u003c\/p\u003e \u003cp\u003eNon-ribosomal peptide biosynthesis 438\u003c\/p\u003e \u003cp\u003eModified peptides: penicillins, cephalosporins, and other β-lactams 458\u003c\/p\u003e \u003cp\u003ePenicillins 458\u003c\/p\u003e \u003cp\u003eCephalosporins 465\u003c\/p\u003e \u003cp\u003eOther β-lactams 469\u003c\/p\u003e \u003cp\u003eCyanogenic glycosides 476\u003c\/p\u003e \u003cp\u003eGlucosinolates 477\u003c\/p\u003e \u003cp\u003eCysteine sulfoxides 480\u003c\/p\u003e \u003cp\u003eFurther reading 481\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Carbohydrates \u003c\/b\u003e485\u003c\/p\u003e \u003cp\u003eMonosaccharides 485\u003c\/p\u003e \u003cp\u003eOligosaccharides 490\u003c\/p\u003e \u003cp\u003ePolysaccharides 493\u003c\/p\u003e \u003cp\u003eAminosugars and aminoglycosides 498\u003c\/p\u003e \u003cp\u003eFurther reading 507\u003c\/p\u003e \u003cp\u003eIndex 509\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":48864638632279,"sku":"9780470741672","price":45.55,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470741672.jpg?v=1722272844"},{"product_id":"crossover-trials-in-clinical-research-9780471496533","title":"CrossOver Trials in Clinical Research","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis text look at cross-over trials which are experiments in which subjects, whether patients or healthy volunteers, are each given a number of treatments with the object being to study the differences between these treatments. They are used extensively in clinical research.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\"…clearly written…mode of presentation is very effective…I recommend this book as a useful resource…\" (\u003ci\u003eJournal of the American Statistical Association\u003c\/i\u003e, December 2004)  \u003cp\u003e\"The book by Senn was the very first volume in Wiley's excellent series, \"Statistics in Practice\".  Here, 10 years later, it is now the first of the books in that series to reappear in a second addition.” (\u003ci\u003eTechnometrics\u003c\/i\u003e, May 2004)\u003c\/p\u003e \u003cp\u003e\"...well structured and easy to read...incredibly useful...\" (\u003ci\u003eApplied Clinical Trials\u003c\/i\u003e, December 2002)\u003c\/p\u003e \u003cp\u003e\"...an excellent reference source and is easily readable.\" (\u003ci\u003eThe Statistician\u003c\/i\u003e)\u003c\/p\u003e \u003cp\u003e\"...explanation are kept as non-technical as possible, although they do not lack statistical rigour...well worth reading...\" (\u003ci\u003ePharmaceutical Statistics\u003c\/i\u003e, Vol 2, 2003)\u003c\/p\u003e \u003cp\u003e“…the main additions can be seen as …adding to the arguments for the author’s view on carryover affects...” (Clinical Trials, No.1 2004) \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003ePreface to the Second Edition.\u003cbr\u003e \u003cbr\u003e Preface to the First Edition.\u003cbr\u003e \u003cbr\u003e 1. Introduction.\u003cbr\u003e \u003cbr\u003e 2. Some Basic Considerations Concerning Estimation in Clinical Trials.\u003cbr\u003e \u003cbr\u003e 3. The AB\/BA Design with Normal Data.\u003cbr\u003e \u003cbr\u003e 4. Other Outcomes and the AB\/BA Design.\u003cbr\u003e \u003cbr\u003e 5. Normal Data from Designs with Three or More Treatments.\u003cbr\u003e \u003cbr\u003e 6. Other Outcomes from Designs with Three or More Treatments.\u003cbr\u003e \u003cbr\u003e 7. Some Special Designs.\u003cbr\u003e \u003cbr\u003e 8. Graphical and Tabular Presentation of Cross-over Trials.\u003cbr\u003e \u003cbr\u003e 9. Various Design Issues.\u003cbr\u003e \u003cbr\u003e 10. Mathematical Approaches to Carry-over.\u003cbr\u003e \u003cbr\u003e References.\u003cbr\u003e \u003cbr\u003e Author Index.\u003cbr\u003e \u003cbr\u003e Subject Index.","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":48864649675095,"sku":"9780471496533","price":97.16,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780471496533.jpg?v=1722272892"},{"product_id":"insulin-pumps-and-continuous-glucose-monitoring-made-easy-9780702061240","title":"Insulin Pumps and Continuous Glucose Monitoring","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003eWhether you are an experienced health care professional working in the field of diabetes technology or fairly new to it all, 'Insulin Pumps and CGM made easy' will provide you with excellent insights into how to get the most from these technologies. This is a 'must have' for the book shelf of those working with people who have Type 1 diabetes.   Dr Emma Wilmot, Chair ABCD Insulin Pump Network UK, Consultant Diabetologist, Derby\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1 An introduction to insulin pumps. 2 Mastering the insulin pump. 3 An introduction to continuous glucose monitoring. 4 Interpretation of continuous glucose monitoring recordings. 5 How healthcare professionals can support people with diabetes to make best use of continuous glucose monitoring. 6 Glucose profile in normal and well-controlled diabetic patients. 7 Abnormalities of glucose profile at night. 8 Abnormalities of glucose profile in relatino to food. 9 Abnormalities of glucose profile in relation to activity. 10 Using continuous glucose monitoring to manage difficult diabetes cases. 11 Sensor-augmented pump therapy.","brand":"Elsevier Health Sciences","offers":[{"title":"Default Title","offer_id":48865573536087,"sku":"9780702061240","price":25.64,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780702061240.jpg?v=1722274566"},{"product_id":"herbs-and-natural-supplements-volume-1-9780729541718","title":"Herbs and Natural Supplements Volume 1","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e","brand":"Elsevier Australia","offers":[{"title":"Default Title","offer_id":48865648509271,"sku":"9780729541718","price":19.5,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780729541718.jpg?v=1722274913"},{"product_id":"pharmaceutical-statistics-9780853694250","title":"Pharmaceutical Statistics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eWritten specifically for pharmacy students, this book explains basic statistics. It contains chapters on basic concepts such as types of data, graphical representation of data, distribution and standard deviation. More advanced statistical techniques, such as ANOVA, are also discussed.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e'This book is a welcome addition to the Pharmacy library...an undoubted strength of the book is its clarity in presentation...the book is highly recommended to any person interested in quantitative aspects of pharmacy...' Prof. Mike Roberts, the Department of Medicine, Department of Practice and Policy, Princess Alexandra Hospital, The University of Queensland, Australia, Journal of Pharmacy and Pharmacology, 1 May 2003\u003c\/p\u003e -- Mike Roberts * Journal of Pharmacy and Pharmacology *\u003cbr\u003e\u003cp\u003e'Pharmaceutical Statistics is well thought out and well written, with a good layout that does not get bogged down with overly complex explanations.' Henry Skupek, Program Support Coordinator, Australian College of Pharmacy Practice, Canberra, Australian Pharmacist, 1 Feb 2003\u003c\/p\u003e -- Henry Skupek * Australian Pharmacist *\u003cbr\u003e\u003cp\u003e'...the book is a useful addition to the range of books available on pharmaceutical statistics.' Alain Li Wan Po, The Pharmaceutical Journal, 7 June 2003\u003c\/p\u003e -- Alain Li Wan Po * The Pharmaceutical Journal *","brand":"Pharmaceutical Press","offers":[{"title":"Default Title","offer_id":48866059059543,"sku":"9780853694250","price":31.35,"currency_code":"GBP","in_stock":true}]},{"product_id":"fasttrack-therapeutics-9780853697756","title":"FASTtrack Therapeutics","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eA guide for students providing bullet points of basic information on therapeutics. It focuses on what pharmacy students really need to know in order to pass exams, providing concise, bulleted information, key points, tips and important self-assessment section which includes MCQs, case studies, sample essay questions and worked examples.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1. Cardiovascular system; 2. Respiratory system; 3. Gastro-intestinal Tract; 4. Renal System; 5. Infectious Diseases; 6. Central nervous system; 7. Endocrine system; 8. The Skin; 9. The Eye; 10. Musculoskeletal Disorders.","brand":"Pharmaceutical Press","offers":[{"title":"Default Title","offer_id":48866059125079,"sku":"9780853697756","price":999.99,"currency_code":"GBP","in_stock":false}]},{"product_id":"pharmacy-osces-9780857110435","title":"Pharmacy OSCEs","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003ePharmacy OSCEs is the only pharmacy-specific OSCE revision guide. This easy-to-use book covers the key competencies that will be tested during your Objective Structured Clinical Examinations whether you are still studying or in practice.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1. Responding to symptoms and history-taking; 2. Systems-based client assessment; 3. Legal aspects of prescriptions, and record-keeping; 4. Data retrieval and interpretation; 5. Clinical prescription management problems; 6. General health advice; 7. Counselling (medication and devices); 8. Problems involving calculations.","brand":"Pharmaceutical Press","offers":[{"title":"Default Title","offer_id":48866068660567,"sku":"9780857110435","price":23.75,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780857110435.jpg?v=1722276888"},{"product_id":"physicochemical-principles-of-pharmacy-9780857111746","title":"Physicochemical Principles of Pharmacy","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\"The text is highly illustrated throughout and includes key points and appropriate examples, providing clinicians with some easily accessible and relevant information. \u003cbr\u003e Some examples of adverse events due to excipients, impurities, the influence of dosage forms, materials in delivery devices and even light-induced effects are also included. Although the detection of adverse events is not an easy task, these examples may assist clinicians in asking the right questions to predict or identify adverse effects. \u003cbr\u003e The new focus on applications to clinical practice in this edition has extended its usefulness from pharmacy and pharmaceutical scientist courses to clinicians seeking an understanding of formulations, especially for children and older people, and in identifying the cause of adverse events.\"\u003cbr\u003e\u003cbr\u003eBeverley Glass, Australian Prescriber October 2016\u003c\/p\u003e -- Beverley Glass * Australian Prescriber *","brand":"Pharmaceutical Press","offers":[{"title":"Default Title","offer_id":48866068693335,"sku":"9780857111746","price":45.6,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780857111746.jpg?v=1722276888"},{"product_id":"introduction-to-pharmaceutical-calculations-9780857111685","title":"Introduction to Pharmaceutical Calculations","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eIntroduction to Pharmaceutical Calculations is an essential study aid for pharmacy students. The book contains worked examples and sample questions and answers.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e1 Introduction; 2 Rational Numbers; 3 Systems of Units; 4 Concentrations; 5 Dilutions; 6 Formulations; 7 Calculation of Doses; 8 Doses in Children; 9 Density, Displacement Volumes and Displacement Values; 10 Calculations Involving Molecular Weights; 11 Parenteral Solutions and Isotonicity; 12 Accuracy of Measurement; 13 Calculations Involving Information Retrieval.","brand":"Pharmaceutical Press","offers":[{"title":"Default Title","offer_id":48866068726103,"sku":"9780857111685","price":31.35,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780857111685.jpg?v=1722276888"},{"product_id":"pharmacy-registration-assessment-questions-4-9780857113849","title":"Pharmacy Registration Assessment Questions 4","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003ePharmacy Registration Assessment Questions 4 features more than 400 entirely new, closed book and calculation questions in line with current GPhC guidance. This revision aid gives you the opportunity to practice a variety of question styles found in the assessment including single best answer questions, extended matching questions and calculations.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003ePreface\u003c\/p\u003e\u003cp\u003eAcknowledgements\u003c\/p\u003e\u003cp\u003eAbout the authors\u003c\/p\u003e\u003cp\u003eAbbreviations \u003c\/p\u003e\u003cp\u003eHow to use this book\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSingle best answer questions\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eSection A\u003c\/p\u003e\u003cp\u003eSection B\u003c\/p\u003e\u003cp\u003eSection C\u003c\/p\u003e\u003cp\u003e\u003cb\u003eExtended matching questions \u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eSection A\u003c\/p\u003e\u003cp\u003eSection B\u003c\/p\u003e\u003cp\u003eSection C\u003c\/p\u003e\u003cp\u003e\u003cb\u003eCalculation questions\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003eSection A\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSingle best answers\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eExtended matching answers\u003c\/b\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003eCalculation answers\u003c\/b\u003e\u003c\/p\u003e","brand":"Pharmaceutical Press","offers":[{"title":"Default Title","offer_id":48866068758871,"sku":"9780857113849","price":33.25,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780857113849.jpg?v=1722276890"},{"product_id":"introducing-palliative-care-9780857114174","title":"Introducing Palliative Care","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eIntroducing Palliative Care is the ideal introductory text for training students in medicine and qualified healthcare professionals in the area of palliative care. The sixth edition has been fully revised in line with current practice and the latest edition of the Palliative Care Formulary (PCF7).","brand":"Pharmaceutical Press","offers":[{"title":"Default Title","offer_id":48866068824407,"sku":"9780857114174","price":23.75,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780857114174.jpg?v=1722276889"},{"product_id":"dale-and-appelbes-pharmacy-and-medicines-law-9780857114204","title":"Dale and Appelbes Pharmacy and Medicines Law","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis new 12th edition of Dale and Appelbeâs Pharmacy and Medicines Law is your guide to law and ethics for pharmacy practice in the UK. It covers law and professional regulation and is firmly established as the definitive student textbook and reference work on this subject in the UK. This edition has been extensively restructured and revised to include all the most recent changes to pharmacy laws and regulation.","brand":"Pharmaceutical Press","offers":[{"title":"Default Title","offer_id":48866068889943,"sku":"9780857114204","price":999.99,"currency_code":"GBP","in_stock":false}]},{"product_id":"palliative-care-formulary-9780857114372","title":"Palliative Care Formulary","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThe eighth edition of the Palliative Care Formulary (PCF), from Pharmaceutical Press, the Royal Pharmaceutical Society's knowledgebusiness, is an essential resource for health professionals who care for patients with progressive end-stage disease.","brand":"Pharmaceutical Press","offers":[{"title":"Default Title","offer_id":48866068988247,"sku":"9780857114372","price":59.36,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780857114372.jpg?v=1722276890"},{"product_id":"dmso-natural-healer-natures-healer-9780895295484","title":"Dmso Natural Healer Natures Healer","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eAn easy-to-understand, up-to-date guide on the highly publicized drug, DMSO\u003c\/b\u003e\u003cbr\u003e \u003cbr\u003eDMSO—dimethyl sulfoxide—is a simple by-product of wood and has been called a “miracle” drug, capable of relieving pain, diminishing swelling, reducing inflammation, encouraging healing, and restoring normal function. In this groundbreaking work, award-winning health science writer Dr. Morton Walker examines the powerful and compelling case for the use of DMSO in the treatment of many debilitating disease and health-related problems. In \u003ci\u003eDMSO: Nature’s Healer\u003c\/i\u003e, Dr. Walker cites documented cases of its astounding use in healing and prevention of a host of health disorders, including arthritis, stroke, cancer, mental retardation, and sports and auto injuries. He also recounts the dramatic story of the long struggle to gain FDA approval of DMSO.","brand":"Penguin Publishing Group","offers":[{"title":"Default Title","offer_id":48866169848151,"sku":"9780895295484","price":15.17,"currency_code":"GBP","in_stock":true}]}],"url":"https:\/\/bookcurl.com\/collections\/pharmacology.oembed?page=122","provider":"Book Curl","version":"1.0","type":"link"}